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1. INTRODUCTION
Silver, known in metallic form since antiquity, has very early
been recognized by mankind for its antimicrobial properties, a
phenomenon observed, for example, in the context of drinking
water (a silver coin in a well), food (silver cutlery, water storage
recipients), and medicine (silver skull plates, teeth).1 Silver
compounds were also shown to be useful. For example, dilute
solutions of silver nitrate served long, and still do in some
countries, as antimicrobial ointment to be instilled into
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newborn babies’ eyes to prevent contraction of gonorrhea from
the mother.1
Used frequently until the middle of the 20th century, silver
and its compounds were then replaced by the newly discovered
antibiotics and nearly forgotten for almost 50 years. However,
one rare example for the use of silver in this time period is silver
sulfadiazine. Upon increasing bacterial resistance against
current antibiotics, and with the steady development of
nanoscale science, research on silver and its compounds has
regained in interest,2 however, facing the challenge to catch up
the time during which research activities in that area were low.
Today, silver presents itself as bulk material, as nanoparticles,
clusters, and a large variety of silver compounds that are
available for numerous applications, one of them being in
medicine.
For ca. 20 years, the number of publications dealing with
silver in medical applications is increasing steadily; for example,
the number of papers corresponding to a search on “silver in
medicine” on the Web of Science database in April 2012 is
given as below ﬁve in 1993, and above 60 in 2011, with ca. 1900
citations in 2011. These publications involve scientists from all
areas: physicists, biochemists, chemists, materials scientists,
microbiologists, and medical doctors, all tackling the problem
from their respective points of view and with their own
methods, respectively, highlighting applications from materials,
analytics, detection, and diagnosis to treatment or drug delivery.
This is, for example, reﬂected in a large number of diﬀerent
assays described to study the antimicrobial properties, the
biocompatibility, and the toxicity in vitro and in vivo, based on
many diﬀerent bacterial strains and cell lines and leading to
sometimes opposite results. If chemists, physicists, and material
scientists tend to know the respective silver compounds used in
their study very well, they usually limit their biological studies
to in vitro antimicrobial tests.3−7 On the other hand, medically
oriented reports are less clear about the exact materials used,
and present more advanced in vitro as well as in vivo results,
the latter of which are sometimes contradictory to in vitro
data.8,9 Besides, the research at diﬀerent scales, for example, at
the macro- and microscopic level (phenomenological observa-
tions), on the one hand, and the molecular studies, on the other
hand, is not always congruent.
Recent reviews and books covered so far individual aspects
of, for example, silver in medicine,10−12 silver coordination
compounds,13 and biomaterials containing silver.14 Other
reports on nanotechnology and its use in medicine contain
also chapters dedicated to silver.15−17
We thus felt it timely to attempt to bring together these
diﬀerent aspects, to collect the data out in the literature, and to
link and present these results of the current state of the art
together with the remaining challenges. This Review addresses
thus many readers: the chemist will learn about the molecular
eﬀects of silver in biological environments; the materials
scientist who is interested in making nanodevices may just as
well ﬁnd interesting examples herein as the microbiologist or
medical doctor who wants to ﬁnd out about the material
composition and its side eﬀects. We focus on four main aspects:
(i) the interaction of silver at a molecular level, on the one
hand, (ii) at a cellular level, on the other hand, (iii) literature
dealing with nanomaterials from which we can learn and get
clues on the functioning of silver at all levels, and (iv) studies
on the biocompatibility of silver. These parts are followed by a
critical discussion of the state of knowledge.
For silver and its compounds, the following sections will
elucidate on the molecular interactions of biomolecules with
silver ions and silver nanoparticles (AgNPs), focusing on
peptides as main reaction partners in cells, then on bacterial
interactions with silver, on the use of silver in biomaterials, and
on the biocompatibility aspects of this metal and its
compounds. We will thus shine light on the diﬀerent aspects
of silver in medicine, exploring the diﬀerent levels of activity,
from the molecular to the cellular and micrometer dimensions.
Silver presents itself in diﬀerent forms; among them ionic silver
and AgNPs are the most frequently discussed in the literature.
We will also present bulk silver surfaces as well as the so-called
nanosilver, a recently described, apparently new class of silver.
For the latter, we will discuss it wherever we ﬁnd the, still rare,
literature.
From a chemical point of view, it is convenient to ﬁrst
highlight interactions of silver at the molecular level because it
is the basis for the interactions at higher levels. Thus, in the
next section, we will start the journey with the examination of
the silver binding to amino acids and peptides.
2. PEPTIDES AND SILVER
2.1. Silver Binding to Amino Acids and Peptides
The interaction of metal ions with biomolecular targets, for
example, amino acids, peptides, or proteins, is known to play a
fundamental role in many biological processes such as electron
transfer reactions, oxygen transport, as well as metal transport
and storage. Further on, the inhibition of enzymes by metal
complexes with labile ligands is well-known. It functions by
ligand exchange reactions, where the labile ligand present in the
administered drug is replaced by the targeted enzyme, a
principle used in many metal-based drugs.18 It is therefore one
of the most important processes in bioinorganic chemistry.19
Although silver ions do not seem to be involved in natural
systems, their medical use makes them an important target.
Ag(I) can be classiﬁed as a soft cation according to Pearson,20
and therefore it prefers to bind to polarizable, so-called soft,
ligands. In addition, it is able to form strong σ−π-bonds
through back-donation of the electrons located in its d-orbitals
to the π*-orbitals of the ligand. In terms of electronic structure,
Ag(I) is closely related to Cu(I) because both ions have the
same outer electronic conﬁguration with a closed-shell structure
(d10). Copper as trace element plays a fundamental role as
cofactor in all organisms.21 Because the presence of larger
amounts of free copper ions is toxic for the cells, many peptides
and proteins are involved in its homeostasis.21 Because of the
close chemical relation between Ag(I) and Cu(I), it is not
surprising that silver has been also found to bind to peptides
and proteins. Because amino acids are the small subunits used
to construct peptides and proteins, it is reasonable to ﬁrst have
a closer look at their interaction with silver ions to answer the
question on how Ag(I) binds to their polymeric form.
2.1.1. Silver Binding to Amino Acids − Theory. The
silver complexes of all common 20 naturally occurring α-amino
acids have been calculated using, for example, the hybrid
density functional theory (DFT)22,23 or the quantitative
structure−property relationship methodology.24 A comparison
of these data is not easy, due to the diﬀerent levels of
calculation, varying basis sets, or the nonidentical treatment of
the basis set superposition error. Nevertheless, these theoretical
studies reveal a common trend, with the three basic amino acids
arginine, lysine, and histidine being the strongest silver ion
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binders, while the nonpolar aliphatic amino acids with the
exception of methionine have the weakest silver ion aﬃnity
among the naturally occurring amino acids, whose side chains
are shown in Figure 1. This aﬃnity is deﬁned as the binding
energy at 298 K. The calculated silver ion aﬃnity of all 20
natural amino acids on the basis of a 1:1 stoichiometry can be
found in Table 1.23 Most interesting for a classical coordination
chemist, cysteine is not among the calculated main candidates
for silver binding even though the sulfur atom is considered as
the softest group present in proteins. Cysteine is therefore,
together with methionine, often considered as preferential
binding site for silver ions in proteins,25 an assumption that is
not conﬁrmed by theory.
The total binding energy can be decomposed into two
energy terms, one for the preorganization of the amino acid and
the second for the interaction between amino acid and cation.
Because this latter interaction is attractive, this term is always
negative and may compensate for the preorganization energy,
which is positive due to the higher energy of the amino acid in
the complexed form (less degrees of freedom) as compared to
their free state. The order in theoretical binding energies for the
metal ion−amino acid complex formation is very similar for
Ag(I) and Cu(I), the main exceptions being proline and serine,
both having a higher aﬃnity toward silver as compared to
copper with respect to the other amino acids. Jover et al.23 also
compared the aﬃnity toward silver with the binding aﬃnities of
the amino acids for other monocharged cations, identifying the
order Cu(I) > Li(I) > Ag(I) > Na(I) > K(I) for most of the
amino acids. The calculated binding aﬃnities also take into
account possible coordination modes between Ag(I) and the
amino acid. While some metal ions are able to adopt diﬀerent
modes, others tend to prefer a single coordination geometry.
These preferences in terms of coordination are thought to be
one important factor on how nature realizes the metal ion
selectivity of metal ion-containing enzymes, which is indis-
pensable for their biological function. The toxicity of some
metals, which are usually not present in biological systems, is
often based on their ability to occupy these (under biological
conditions) metal-speciﬁc binding sites through eﬀective
competition with the biologically relevant metal ion and strong
coordination to its binding site.26 In principle, there can be up
to three diﬀerent coordination sites present in an amino acid:
(i) the amino nitrogen-donor at the N-terminus, (ii) the oxygen
atoms of the carboxylic group of the C-terminus, and if present
(iii) the heteroatom-containing side chains. A selection of
possible coordination modes for the Ag(I) complexes of amino
acids is given in Figure 2.24 The binding can either occur
without or with the help of the side chain. In the ﬁrst case, the
amino acid acts as bidentate ligand either via both termini (1
and 2) or via both oxygen atoms of the carboxylic group of the
C-terminus (3 and 4). If the silver binding occurs with the help
of the side chain, the amino acid can either act as tridentate (5)
or bidentate ligand (6 and 7).
In theory, monodentate coordination via only one
heteroatom is possible as well, leading to a 2:1 complex
between the amino acid and silver with respect to the preferred
metal ion coordination number of two of the metal ion.
However, because there is no stabilizing contribution due to
chelation for the monodentate forms, they are expected to be
higher in energy. Hopkinson divided the structures of silver−
amino acid complexes obtained by theoretical studies into three
major categories.27 The ﬁrst one represents ﬁve-membered
cyclic structures with the silver ion dicoordinated by the two
termini (1−3). Members of the second category coordinate
Figure 1. The 20 common natural α-amino acids classiﬁed according
to their side chain R.
Table 1. Calculated Enthalpies ΔH° and Free Energies ΔG°
(kJ mol−1) for the Amino Acid−Ag(I) Complexes
α-amino acid ΔH°a ΔG°a
glycine (Gly) 206.1 170.1
alanine (Ala) 212.8 176.8
valine (Val) 216.1 181.0
leucine (Leu) 219.5 185.6
isoleucine (Ile) 221.1 188.9
serine (Ser) 224.5 190.2
cysteine (Cys) 230.2 194.4
threonine (Thr) 233.2 199.8
aspartic acid (Asp) 232.4 199.0
proline (Pro) 234.5 199.8
phenylalanine (Phe) 236.2 198.6
glutamic acid (Glu) 239.9 203.1
tyrosine (Tyr) 239.9 202.3
asparagine (Asn) 250.8 217.4
tryptophan (Trp) 260.0 221.5
methionine (Met) 262.1 219.9
glutamine (Gln) 264.2 225.5
histidine (His) 284.2 249.1
lysine (Lys) 296.8 260.8
arginine (Arg) 336.5 279.8
aEstimated from ref 23.
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Ag(I) by three or four atoms, yielding structures with multiple
rings (5), while the members of the last group bind Ag(I) via
the carboxylate of their zwitterionic form in a bidentate fashion
(4). Further on, the members of the ﬁrst two categories have
been described as charge-solvated because the silver ion is well
solvated by the amino acid in the gas phase, while the last group
forms salt-bridge structures.22 Structure 1 was found to be the
predominant coordination mode of unpolar aliphatic amino
acids with hydrogen or alkyl groups in their side chain. The
Ag(I) is symmetrically coordinated by the two termini with
almost identical Ag−N and Ag−O distances, for example, 2.418
and 2.390 Å in case of the Ag(I)−glycine complex.26 The
Ag(I)−proline complex is the only case where the salt bridge
structure 4 is favored over the charged solvated forms.23 This is
probably, on the one hand, due to the constraints of the ﬁve-
membered ring that do not allow the optimum orientation of
the lone pair on the nitrogen atoms, and, on the other hand,
due to the larger basicity of the secondary amine. All of the
remaining amino acids are predicted to coordinate in a
tridentate fashion with side chain participation (5). In these
cases, the silver-coordination bonds with the termini are
elongated as compared to the bidentate structures of the
unpolar, aliphatic amino acids (by ca. 0.050 Å) due to the
participation of the third coordination site. For the four amino
acids possessing the highest proton aﬃnities (Arg, Lys, His, and
Gln), the additional Ag−X bond is calculated to be shorter than
those with the termini, indicating a stronger binding of the side
chain.
After having discussed the theoretical work on coordination
of amino acids toward silver, we will in the next subsection
focus on experimental eﬀorts undertaken in this research area.
2.1.2. Silver Binding to Amino Acids − Experiment. To
our current knowledge, the only experimental data for the
Ag(I) aﬃnity of all 20 naturally occurring amino acids (with the
exception of Cys) have been provided by Siu and co-workers,28
who also determined the binding energies of the silver ion to
simple alcohols and amides.27 They determined the relative
silver ion aﬃnities of the amino acids using relative ΔG° values
obtained by the kinetic method developed by Cooks and co-
workers.29 The basis of this method is the competitive
decomposition of a set of ion-bound heterodimers, whose
general structure in case of the determination of silver binding
aﬃnities can be described as [AaaxAgAaay]
+ (Aaax and Aaay
representing two diﬀerent amino acids). The so-obtained
experimental data28 are in good agreement with the previously
described DFT calculations23 (Table 1).
Considering the number of amino acids, possible coordina-
tion modes (see section 2.1.1) and crystallization conditions,
the structural information for silver−amino acid complexes
based on X-ray structures is still rare. This is at ﬁrst glance quite
surprising because a detailed analysis of the coordination
chemistry of amino acids is a prerequisite for the understanding
of bioinorganic reaction mechanisms since they serve as model
compounds for peptide−silver interactions.30 However, the
relatively little amount of published crystal structures
summarized in Table 231−41 can be explained by the fact that
the resulting compounds are diﬃcult to synthesize because they
are light sensitive in solution and poorly soluble in common
solvents.39 Nomiya and co-workers recently showed that for
alanine and asparagine the light stability of the silver complex
can be enhanced with additional triphenylphosphine ligands38
or by acetylation of the N-terminus40 of the amino acid. To
further classify the binding modes of Ag(I) in these structures
(with the exception of sulfur-containing compounds), the
following classiﬁcation was proposed:39 the silver ion is
involved (i) only in Ag−O bonds (bond length <2.6 Å),42
(ii) only in Ag−N bonds (bond length <2.5 Å),42 or (iii) in
both Ag−O and Ag−N bonds.
The summary in Table 2 shows that the latter class is the
most frequent one. Further on, it reveals that in the published
structures the coordination geometry around the silver ion is, as
expected, preferentially linear, leading either to 1D coordina-
tion polymers or to dimeric structures (e.g., for a silver to
amino acid ratio of 1:2). For some of the presented structures,
the Ag−Ag distance is so short that the interaction of both d10
ions becomes discussable43,44 because the bonds are shorter
than the van der Waals diameter of 3.44 Å45 and in the range of
the distance of 2.88 Å46 found in metallic silver. It is surprising
that among the few published structures there is a reasonable
amount of structures with amino acids, which were calculated
to be weak silver binders because they allow no side chain
participation.
2.1.3. Silver Binding to Peptides. Going from amino
acids to peptides, the number of coordination sites per
molecule increases and the backbone amide can function as
an additional coordination site as well. Shoeib and co-
workers26,47 investigated the structure and free energy of di-
and tripeptides by means of DFT calculations. For the
investigated silver−peptide complexes, they found structures
at low energy minima with coordination numbers between two
and four. Tricoordinated systems were found in the case of
dipeptides, while tri- and tetracoordination were observed for
tripeptides. As one might expect, experimental data based on X-
ray crystallography are even less abundant for silver−peptide
complexes than for amino acids. To our current knowledge, the
only published structure is the one published by Acland and
Freeman31 for Gly−Gly, the simplest of all dipeptides. At pH =
6, this dipeptide forms a dimeric complex 8 in which two silver
Figure 2. Selection of possible coordination modes between Ag(I) and
amino acids. R represents the side chain of the amino acid in general, if
it does not participate in the silver binding, while X represents the
coordinating heteroatom present in the side chain.
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ions connect the C-termini of the dipeptides via Ag−O bonds,
forming an eight-membered ring (Figure 3). Even for peptides
frequently used in combination with silver such as glutathione
(GSH) (see section 2.2) or the AG4-peptide (see section
2.3.1), no crystal structure has been published. For glutathione,
for example, there is only a proposed structure published for
the GSH−silver complex, which is based solely on solid state
13C nuclear magnetic resonance (NMR) and infrared (IR)
spectroscopy.48 Besides, a recent review on metal−peptide
frameworks does not describe such structure in combination
with silver,49 underlining the diﬃculty in obtaining suitable
crystals.
Even though there is not so much known about the detailed
coordination behavior of silver toward peptides, the variety of
sites suitable for metal binding can be capitalized in mass
spectrometry (MS) because the use of metal ions as cationizing
agents is widespread. Ag(I) has been used for the character-
ization of peptides as well. Electrospray in combination with
collision-induced dissociation (CID) of Ag(I) complexes of
amino acids and smaller peptides revealed, for instance,
common fragmentation pathways, yielding predominantly N-
terminal ions, which is in contrast to the behavior of protonated
peptides normally present using standard conditions for
MS.50−52 However, due to the formation of doubly charged
ions resulting from the complexation of Ag(I) and a proton, the
fragmentation pattern and its interpretation are rather
complicated. This problem was solved using matrix-assisted
laser desorption/ionization (MALDI) in combination with
CID, which allowed for the sequencing of larger peptides and
proteins and might in the future also be used for the de novo
sequencing of peptides and proteins.53 The analysis of
nonfragmented peptides complexed with silver is possible by
means of MALDI time-of-ﬂight (TOF) MS. Through the
addition of triﬂuoroacetic acid (TFA) to the sample, the
number of Ag(I) complexes can be reduced as compared to the
TFA-free solution due to the protonation of the basic amino
acid residues, thus providing additional information,54 but not
necessarily reﬂecting complexes formed at biological pH.
Besides MS, Ag(I) is also employed as an analytical tool in
other spectroscopic ﬁelds. Interestingly, it can be used to
selectively detect the level of cysteine in biological ﬂuids,
although in theory Cys is not among the amino acids with a
high silver ion aﬃnity (Table 1).55 This detection is of great
interest because the amount of cysteine present in physiological
samples was found to be an important marker for clinical
disorders.56,57 The addition of Ag(I) to a cysteine-containing
solution leads to a self-assembly of chiral complex nanoparticles
consisting of Ag(I) and cysteine. The formation of these
particles results in a signiﬁcant change in the circular dichroism
(CD) spectra, which is not observed for the other naturally
occurring amino acids or related biologically relevant thiols
such as glutathione or homocysteine. Therefore, this CD
method seems to be a promising probe for cysteine, working
selectively and at a micrometer level.55 These results were
recently conﬁrmed by an independent work of Jiang and co-
workers,58 focusing on a mechanistic analysis. They could show
that interactions between the silver atoms, the so-called
argentophilic attractions, can be switched on and oﬀ depending
on the pH resulting in a decrease of the CD signal with
increasing pH as a consequence of the loss of the argentophilic
attraction due to the electrostatic repulsion of the carboxylates
present at high pH values.58
A strong interaction between silver ions and cysteine was also
reported by Feng at al.59 for their on−oﬀ sensor for silver ions
and cysteine based on desoxyribonucleic acid (DNA)-function-
alized gold nanoparticles. In this system, cysteine is able to
remove Ag(I) from the cytosine−Ag(I)−cytosine base pair
complex (oﬀ-signal) that was responsible for a DNA duplex
formation detected by light scattering (on-signal).59
As a concluding remark, the interaction of cysteine with ionic
silver seems to be underestimated if taking into account only
the binding aﬃnities presented in Table 1. However, its role
should also not be overrated as the only important binding site
in peptides and proteins because other amino acids such as
histidine are excellent silver binding sites as well. After this
overview of the interaction of silver ions with simple amino
acids and short peptides, the following sections will focus on
natural peptides and their role in metal detoxiﬁcation and
peptide-mediated formation of silver nanostructures.
2.2. Natural Peptides Involved in Metal Detoxiﬁcation
To the best of the authors’ knowledge, Ag(I) is not essential for
biological processes. However, nature has to deal with silver
ions present either naturally in the environment or due to the
widespread use of silver, for example, in the photographical
industry or medicine. Concerning the toxicity of silver,
especially its accumulation is important, which is more often
found in aquatic ecosystems than in their terrestrial counterpart
as is typical for heavy metals.60 Therefore, bacteria and higher
organisms had to develop resistance mechanisms to render
Ag(I) and other toxic metal ions innocuous. Some bacteria
developed a rather complex resistance machinery that also
involves the use of silver binding proteins, which will be
discussed in detail in section 3.2. Many organisms respond to
heavy metal stress with the synthesis of binding proteins such
as metallothioneins (MT), which can complex the harmful
metal ions.61 They are ubiquitous and thought to be important
for a wide range of biological functions such as transport,
storage, and, as just mentioned, detoxiﬁcation of essential and
nonessential trace metals. After giving a short introduction of
this class of low molecular weight proteins, whose aﬃnity to
silver is well-known,62 we will only focus on the work related to
Ag(I).
The ﬁrst MT was discovered in 1957, when this name was
given to a metal-containing cysteine-rich protein, isolated from
equine renal cortex.63 By deﬁnition, members of this family of
proteins (i) are of low molecular weight, (ii) possess a high
metal and sulfur content, (iii) have a characteristic amino acid
composition, which is cysteine-rich but lacks the aromatic
amino acids, and (iv) coordinate to metal ions through
mercaptide bonds, due to the fact that all Cys residues are
present in their reduced state, which gives rise to characteristic
spectroscopic features of metal−thiolate clusters.64 These
characteristics can be found in numerous peptides and proteins
in many organisms. Therefore, the MTs are subdivided into
Figure 3. Schematic representation of the silver−diglycine complex 8
formed at pH = 6 according to Acland and Freeman.31
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three classes, with polypeptides in class I having cysteine
locations closely related to those in the ﬁrst reported MT;
members of class II, the biggest class of MTs, having locations
of cysteins only distantly related to those in equine MT; and
class III comprising metal−thiolate polypeptides that are not
genetically coded.65 In their metal-free (apo) form, the MTs
lack almost any secondary structural elements. Therefore, an
ordered spatial structure is only observed in the metal-
containing (holo) form induced by the presence of metal
ions. Among others, this is one reason why three-dimensional
structures of MTs are rare, no matter if taking into account
computed or crystal structures.66
Because Ag(I) is NMR-active, it is discussed as a good probe
for Cu(I) in the structure determination of Cu-containing
peptides and proteins. However, structural diﬀerences might
arise from silver’s larger ionic radius67 (Ag(I) 137 pm, Cu(I)
77 pm) and from Ag(I) preferring a linear over a trigonal planar
(or tetrahedral) coordination geometry as preferred by Cu(I).
There is so far no silver-containing crystal structure of MTs
reported in the literature and only one solution structure for
yeast-MT based on NMR data, which is shown in a simpliﬁed
way in Figure 4.68 Peterson et al.68 published this theoretical
structure for a truncated yeast-MT (the ﬂexible C-terminal end
was excluded from the calculation) resembling a sprung
paperclip, with the peptide backbone folding around a cluster
of seven Ag(I). It forms two parallel loops that are separated by
a deep cleft containing the metal cluster. This structure is very
similar to the analogue Cu(I) species, which has been
calculated as well. For the Cu(I)-MT, there are only slight
contractions and a more ﬂexible N-terminus. The latter is
probably due to the lack of N-terminal hydrogen bonding.
Additionally, there is evidence that the coordination of one of
the metal ions is diﬀerent in both structures with Cys969
coordinating only in the copper-containing protein. However,
this is an encouraging example for the structure prediction of
Cu(I) proteins with the help of Ag(I) derivatives.
The strong aﬃnity of MTs toward metal ions has also been
used in the fabrication of biosensors for various heavy metals,
including the detection of Ag(I) in drinking water. In 2009, a
potentiometric sensor was described, using Ag(I) selective
electrodes.70 This selectivity was achieved by the incorporation
of MTs into the membrane with poly(arylether sulfone) as
polymeric matrix. Besides Hg(II), the other tested metal ions
caused no or merely minor interferences, and the limit of
detection was estimated to be around 10 μM (1079 μg L−1). A
few months later, Kizek and co-workers71 proposed an
electrochemical biosensor for the detection of Ag(I) based on
MTs adsorbed on the surface of a hanging mercury drop
electrode. The detection limit for Ag(I) was estimated to be
0.5 μM (53.9 μg L−1), which is 20-fold more sensitive than the
matrix-bound MT sensor. Still, this device is not a high
precision instrument, but it is rather cheap, easy to use, and
sensible enough to detect Ag(I) in contaminated drinking water
because the maximum allowed contaminant level in drinking
water is approximately 1 μM (107.9 μg L−1) depending on the
country.72 Recently, the same group was able to present a new
electrode with a 1000-fold lower detection limit of 0.5 × 10−3
μM (53.9 × 10−3 μg L−1). They used a carbon paste electrode
that has been decorated with MTs via anti-MT antibodies.73
This strong interaction might be a key factor for the low
detection limit because the MTs are better captured on the
electrode surface as compared to simple adhesion as in case of
the hanging mercury drop electrode. As for the potentiometric
determination described above, Hg(II) is the only ion
interfering with the measurement, due to its higher aﬃnity to
MTs as compared to Ag(I).74 The main advantage for this
system besides its low detection limit is claimed to be the easy
miniaturization that could lead to the development of new
working electrodes out of carbon nanomaterials immobilized
with MTs.73
Another important type of peptides in terms of metal
detoxiﬁcation is phytochelatins (PC), which are classiﬁed as
class II MTs.75,76 These enzymatically synthesized peptides are
produced by plants upon the exposure of the cells to toxic
metals including silver. Such metal ions activate the PC
synthase that catalyzes the conversion of GSH to PC (Figure
5). Their general structure is (γ-Glu-Cys)nX, with X being Gly
(PCs), β-Ala, Ser, or Glu (iso-PCs) and n commonly being in
the range between 2 and 4, but also higher values (up to
n = 11) have been reported.75 The PCs function as potent
complexing agents in the cytosol of the cell and in this way
preserve the cell from damage due to the heavy metal ions.
Recent electrochemical studies77 conﬁrmed that the amount of
thiols such as phytochelatin and glutathione produced by plant
embryos is proportional to the Ag(I) concentration and the
time of exposure. This is in agreement with the current
understanding that these molecules are part of the plant’s
defense system against heavy metals,77 in which the PCs−metal
complexes are transported into vacuoles78 where the metal ion
is less harmful.
Figure 4. Schematic representation of the solution structure of the
truncated Ag(I)-coordinated yeast metallothionein, which lacks
structural motifs in its apo-form. The numbers indicate the position
of the 10 Cys-residues that are responsible for silver binding that is, in
turn, the driving force for the protein folding. Adapted with permission
from ref 68. Copyright 1996 Elsevier.
Figure 5. The enzymatic synthesis of PC starting from GSH.
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Recently, there has been a growing interest in glutathione
itself due to its ability to form stable hydrogels together with
Ag(I) depending on the silver/thiol ratio.79,80 The self-
assembly of both components is proposed to lead to the
formation of a polymeric network, stabilized by Ag(I)−Ag(I)
attractions, which were already discussed for the crystal
structures of silver−amino acid complexes (see section 2.1.2),
and additional noncovalent interactions such as hydrogen
bonds as evidenced by Fourier-transform (FT) IR. The so-
called argentophilic gel is stable in the pH range from 2 to 5
and can be converted reversibly into a clear solution through
addition of an acid or a base, respectively, and can therefore be
assigned as pH-responsive. The interaction with Ag(I) seems to
be only based on the presence of the thiol function in GSH,
whose stretching band is absent in the formed Ag(I) thiolate
(GS-Ag).79 One future perspective is the use of these hydrogels
as drug delivery system with the thiol component being not
GSH itself but a thiol-containing drug. As proof of principle,
the mucolytic drug N-acetyl-L-cysteine was used for the
formation of argentophilic hydrogels.81 Furthermore, GSH-
based argentophilic hydrogels were recently reported to act as
an iodide-responsive material with the iodine functioning as a
depolymerizing agent82 or as a ratiometric luminescent sensor
for the presence of Ag(I) using a modiﬁed GSH carrying an
aromatic ﬂuorophore.83 Another possible application of silver-
GSH hydrogels lies in the biomedical ﬁeld. Tang and co-
workers84 showed that the addition of Ca(II) leads to cross-
linking, thus decreasing the solubility of the gel in water, which
is favorable for a slow release of silver as an antimicrobial
compound. Indeed, they could show that after a fast initial
silver release in buﬀered saline during the ﬁrst hours, the release
continues up to 6 days as it was determined by inductively
coupled plasma (ICP) method. The release of silver ions is
thought to be triggered by the leakage of the cross-linking
Ca(II), leading to the gradual destruction of the hydrogel
accompanied by silver ion release.
Both PCs and GSH have lately been used for the synthesis of
AgNPs due to their good ability to encapsulate the growing
particle, and thus terminating the growth of AgNPs.85 This
capping is crucial for the stability of metal nanostructures in
general. Moshe and Markovich,86 for example, used GSH for
the preparation of hollow AgNPs, using GSH-stabilized silver
oxide nanoparticles that were chemically reduced in a counter
diﬀusion process. Recently, it was shown that GSH can be more
than a simple capping agent because it can be used as an anchor
for further protein modiﬁcation of the stabilized AgNPs. Thus,
Wu et al.87 successfully synthesized surface-modiﬁed AgNPs
with the help of GSH (see section 2.3.1). The thiol group of
GSH absorbs on the silver surface and its N-terminus serves as
an anchoring group for a glutaraldehyde linker via the
formation of a secondary imine. The second aldehyde function
is used for the covalent attachment of a protein such as bovine
serum albumin as a model compound.87 The use of PC as a
capping agent was demonstrated, for example, by Kumar et al.88
for an enzymatic route toward AgNPs using the enzyme nitrate
reductase for the silver reduction in combination with PC as
the capping agent.
The general ideas presented in this section for peptides
involved in metal detoxiﬁcation will in the following section be
extended to peptides in general, which were either discovered
by aﬃnity screenings or synthesized de novo.
2.3. Peptides for the Formation of Silver Nanostructures
As will be demonstrated in section 3.3 on the example of
bacteria, it is known that microorganisms are able to form
AgNPs. This process is embraced by the generic term
“biogenesis of inorganic nanoparticles”. It has already been
reviewed in recent publications,89,90 as well as the work on
protein and peptide-directed production of inorganic materials
in general.91,92 The advantages in the use of peptides in these
syntheses are among others the mild reaction conditions as
compared to traditional procedures enabling the green
synthesis of nanomaterials and the high control they oﬀer
over the size and shape of the formed material.91 This Review is
focused exclusively on silver nanomaterials where either the
peptides are used for its biomineralization and therefore are
responsible for silver reduction, or they serve as structure-
determining scaﬀold and stabilizing agent while the reduction
of Ag(I) to Ag(0) is performed by an additional reducing agent.
2.3.1. Biomineralization of Silver by Means of
Peptides. The process of biomineralization comprises the
nucleation, growth, and assembly of inorganic materials by
biological systems.93 Examples for biomineralization-derived
materials are among others the shells of diatoms (silicium
dioxide), pearls and shells (calcium carbonate), as well as bones
(hydroxyapatite (HA) = [Ca10(PO4)6(OH)2]). During the
biomineralization process, peptides can function as a structural
template controlling the size and shape of the formed
material.91 When it comes to the peptide-mediated formation
of silver nanostructures, the peptides may serve not only as
scaﬀold, but as a reducing agent as well. A huge eﬀort has been
made to understand the mechanism of nanoparticle formation
by microorganisms (see section 3.3). Nonetheless, even for one
of the most prominent examples, Pseudomonas stutzeri
(P. stutzeri),94 this process is still not fully understood. In
addition, it is not always easy to identify the active biomolecule
responsible for biomineralization produced by microorganisms
or plants. These active biomolecules do not necessarily have to
be peptides. With the extract of coﬀee or tea, for example, the
AgNP formation is due to the presence of polyphenolic
compounds like catechins or the xanthine alkaloid caﬀeine.95,96
However, it has been shown that peptides do play an important
role in the formation of AgNPs. To identify the ones
responsible for silver binding and precipitation, the phage
display technique (Figure 6), which was developed in 1985 by
Smith,97 had an enormous impact.98 Rodi and Makowski99
described the power of this technique called biopanning with
the successful search for a needle in a molecular haystack. The
haystack consists of a peptide library in which each peptide is
displayed on the surface of a bacteriophage viron by inserting
foreign DNA segments into an appropriate location within the
phage genome. This physical linkage of the DNA encoding the
displayed peptides later allows their identiﬁcation and is the
basis of this technique. This phage display library is incubated
with the desired target, in our special case the surface of AgNPs,
allowing the peptides to interact with the target. This selection
step is also termed “panning”. After all of the unbound phages
are washed away, the bound ones are eluted by changing the
pH and eventually ampliﬁed for an additional panning cycle
improving the screening result. Their peptide sequence can
then be determined by deciphering the inserted nucleic acid.
Stone and co-workers100 demonstrated that for very strongly
interacting peptides this standard procedure has to be adapted
because these strong binders are not eluted within the acidic
washing step and therefore would get lost. To overcome this
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problem, they developed a novel screening method based on
the polymerase chain reaction (PCR) schematically shown in
Figure 6. This PCR-driven method allows the ampliﬁcation of
the phage DNA fragment including the region encoding the
displayed peptide, whose amino acid sequence can be
determined by DNA sequencing. The improvement obtained
by the PCR-driven screening was demonstrated on the
screening of a library for the detection of silver-binding
peptides. While with the regular panning only three peptides
could be identiﬁed,101 the improved screening located 14
additional peptides capable of silver-binding and reduction.100
The use of rolling cycle ampliﬁcation is supposed to further
improve the results of the phage display technology because it
allows for the direct ampliﬁcation of phage DNA while it is still
bound to the substrate.102
One of the best studied examples of the silver-binding
peptides detected by biopanning is the dodecapeptide Asn-Pro-
Ser-Ser-Leu-Phe-Arg-Tyr-Leu-Pro-Ser-Asp named AG4 that
was discovered by Naik et al.101 Its three-dimensional chairlike
structure was predicted with the help of NMR data, and the
amino acids Leu5, Phe6, and Arg7 were found to be the ones
whose NMR signals were most shifted upon the addition of
Ag(I).103 It was therefore concluded that those residues are
responsible for the interaction with silver. This example shows
that calculated binding aﬃnities for amino acids (Table 1) are
not necessarily conﬁrmed in peptides. Nowadays, it is well
known that peptides targeting inorganic materials such as silver
are often able to mineralize the targeted elements as well,
forming nanostructures. Naik et al.101 showed not only that the
AG4 peptide is capable of reducing Ag(I) yielding, according to
an analysis by transmission electron microscopy (TEM),
AgNPs with sizes of 60−150 nm and hexagonal, spherical, or
triangular shapes, but they demonstrated further that this
peptide can be used for the generation of silver crystal arrays on
a glass surface using micromolding in capillaries. The
interaction of the AG4 peptide with silver also gives rise to
other applications. One example was recently reported where
the AG4 peptide in connection with AgNPs was used for
Raman spectroscopic conformational studies of large proteins
interacting with silver surfaces.104 For this purpose, the AG4
peptide was fused to the C-terminus of a protein that itself
shows only little aﬃnity to AgNPs used as surface enhancers for
Raman spectroscopy. Such a short terminal extension is
normally well tolerated, and in this case increases the binding
and orientation of the protein, thus improving the quality of the
obtained data. This method might be useful for the
investigation of peptide conformation and orientation on
other surfaces used in biotechnological applications, for
example, aluminum or platinum.104 A second example for the
use of the AG4 peptide is the fabrication of silver nanowires.
For this purpose, the encoded AG4 peptide was genetically
fused to the gene of a protein acting as scaﬀold.105 After
expression and puriﬁcation, the scaﬀold proteins self-assemble,
induced by guanosine-5′-triphosphate, into nanometer-scale
ﬁbers, decorated with the silver reducing AG4 peptide.
Incubation with Ag(I) resulted in almost completely silver-
coated nanowires. Authors claim that with optimized coating
conditions the fabrication of continuous silver-coated nano-
wires should be possible.105
Another peptide capable of producing AgNPs was identiﬁed
by Sano et al.106 They reported an interesting cross selectivity
for a titanium-binding dodecapeptide (TBP-1) with the primary
structure Arg-Lys-Leu-Pro-Asp-Ala-Pro-Gly-Met-His-Thr-Trp,
which was discovered by means of biopanning as well. Out of
10 diﬀerent metals, TBP-1 was able to mineralize silver in
addition to silicium and titanium, forming AgNPs with a size in
the range of 300−500 nm and a rectangular shape. For the
formation of silver, silica, and titanium, the three amino acids
Arg1, Pro4, and Asp5 are essential because the substitution of
either one of them by alanine results in nonactive peptide
mutants.106 It should be kept in mind that mutation
experiments provide a ﬁrst insight into the binding mechanism,
but for a deeper understanding, for example of conformational
changes upon silver binding, NMR studies or single-crystal X-
ray diﬀraction are able to provide more detailed information.
Very recently, the ﬁrst in vivo study using engineered metal-
binding peptides was published in which Escherichia coli
(E. coli) secretes a short metal binding protein (Glu-Gln-Leu-
Gly-Val-Arg-Lys-Glu-Leu-Arg-Gly-Val that was before identi-
ﬁed by biopanning) either into the periplasm or into the
cytoplasm.107 Interestingly, the strains possessing the peri-
plasmic version of the peptide were able to survive in the
presence of ionic silver (28 μM, 3020 μg L−1), while the ones
with the peptide located in the cytoplasm showed no resistance.
Because AgNPs located in the periplasm were observed by
TEM analysis for the silver-tolerant strain, it is proposed that
the peptides are involved in the accumulation and reduction of
ionic silver, thus forming less soluble and therefore less toxic
NPs.107 This purely peptide-mediated resistance has so far not
been reported for natural systems, but it could be an additional
resistance mechanism to the ones presented in section 3.2.
The number of organisms and with that the number of
peptides that are known to be able to produce nanosized silver
is still growing, but the fundamental principles behind this
Figure 6. Schematic depiction of the standard biopanning method
(path A) and the modiﬁed PCR-driven procedure (path B) for the
sequence determination of silver-binding peptides. Adapted with
permission from ref 100. Copyright 2004 Wiley-VCH Verlag GmbH &
Co. KGaA, Weinheim.
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fascinating process are still not understood to a satisfactory
level. Even though many studies only described the
phenomenon of silver reduction by means of peptides and
did not go for a more detailed mechanistical analysis of this
process, there soon was an agreement on the fact that the size
and shape of the formed nanostructures are inﬂuenced by the
peptide sequence.
The Role of Tyrosine. Xie et al.108 performed one of the
most detailed studies of a biological AgNP synthesis by
analyzing the extract of the green algae Chlorella vulgaris
(C. vulgaris), which is capable of forming silver nanoplates.
They ﬁrst identiﬁed algal proteins to be the active biomolecules
in this extract because under denaturing conditions, for
example, heat or urea they found smaller nanoplates as
compared to the nonmodiﬁed extract (average size of 27 nm
versus 44 nm). With only the size being inﬂuenced, the
conclusion was that upon denaturation more amino acids
become accessible for the interaction with silver. They went
one step further and tried to identify the key players among the
amino acids responsible for silver interaction and reduction. By
Fourier transform (FT) IR, ﬂuorescence analysis, and the use of
acetylated derivatives, they could show that Tyr residues are
responsible for the silver reduction by these algal proteins.108
Earlier, Selvakannan et al.109 already reported that tyrosine is
able to reduce Ag(I) under alkaline conditions due to the
deprotonation of the phenolic group and proposed a
semiquinone as its ﬁnal oxidation product.110 Xie et al.108
modiﬁed this model for neutral tyrosine with the ﬁrst step
being the coordination of Ag(I) acting as a Lewis acid and
binding to the hydroxyl group. In total, one tyrosine is claimed
to reduce two Ag(I) generating two protons and the
semiquinone with a neutral tyrosyl radical generated as an
intermediate.108 These stable radicals, formed upon the loss of a
proton and an electron, are well-known intermediates in
electron transfer processes, for example, in natural systems such
as in the enzyme ribonucleotide reductase as the most
prominent example111 or have been detected in designed
model peptides used for the determination of rate constants of
electron transfer steps.112 The tyrosyl radical can therefore be
considered as a probable intermediate involved in the reduction
of Ag(I) as well. However, the semiquinone 9a being the
proposed ﬁnal oxidation product of tyrosine (9b) as depicted in
the literature108−110 is not an oxidized form of tyrosine but one
of its tautomeric forms and therefore cannot be the ﬁnal
oxidation product upon silver reduction (Figure 7a). Because
the oxidation of p-cresol (10) by cytochrome P450 was shown to
lead to the formation of a very reactive quinone methide
intermediate 11, which can then be trapped by glutathione to
yield the GSH-conjugate 12 as shown in Figure 7b, a similar
intermediate might be discussed for the oxidation of
tyrosine.113 However, this tyrosine analogue of 11 was to the
best of our knowledge only once reported in the literature.114
For further insight in the tyrosine-mediated reduction of Ag(I),
the work on gold nanoparticle formation has to be taken into
account. Mandal and co-workers115 postulated that starting
from a tyrosinate-containing peptide 13, a neutral radical 14 as
an intermediate is formed, which was detected by electron
paramagnetic resonance (EPR) spectroscopy. This radical
recombines with a second tyrosine radical to form dityrosine
(15) as tyrosine’s ﬁnal oxidation product (Figure 7c), which in
turn can be detected easily through its emission peak at around
410 nm. In proteins, such formation of dityrosine leads to
cross-linking of peptides, which can be either a normal process
or a pathological response to disease or oxidative stress.116
An analogue redox process is likely involved in the formation
of AgNPs as well. Both, Si et al.115 and Xie et al.108 reported
that the tyrosine content in tripeptides as model compounds
for larger proteins inﬂuences the rates of silver108 or gold115
nanoparticle formation. Another important factor inﬂuencing
the rate of tyrosine-mediated mineralization is the pH value of
the reaction medium as it was, for example, shown for tyrosine-
and ruthenium-containing model compounds mimicking the
photosystem II, where they proposed a proton coupled electron
transfer for tyrosine (pH < 10) and a faster single electron
transfer step starting from tyrosinate (pH > 10).117 The same
trend was observed by Mandal and co-workers115 for the
formation of gold nanoparticles by means of tyrosine-
containing peptides. Xie et al.108 did not study the inﬂuence
of the pH on the AgNP formation but discussed the inﬂuence
of the silver−peptide complex formation on the redox potential
of the Ag(I)/Ag(0) couple showing that complexation
generally lowers the redox potential and therefore facilitates
the reduction of Ag(I) (see Table 3). They underlined their
Figure 7. (a) Two possible tautomeric forms of tyrosine. (b)
Oxidation of the related p-cresol (10) leads to the quinone methide
intermediate 11 trapped with GSH (→12). (c) Dityrosine formation
(15) as a possible oxidation pathway of tyrosine.
Table 3. Standard Electrode Potential E° in Volt for
Diﬀerent Silver Compounds
red ⇌ ox +ze− E°
Ag (bulk) ⇌ Ag+ +e− 0.80
2Ag + 2OH− ⇌ Ag2O + H2O +2e
− 0.34
Ag + Cl− ⇌ AgCl +e− 0.22
Ag + Br− ⇌ AgBr +e− 0.07
Ag2 ⇌ Ag + Ag
+ +e− −0.10
Ag + I− ⇌ AgI +e− −0.15
Ag3 ⇌ Ag2 + Ag
+ +e− −0.95a
Ag (atom) ⇌ Ag+ +e− −1.80
aEstimated from ref 119.
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statement with experiments using a series of tripeptides all
containing a C-terminal tyrosine and the two remaining amino
acids bearing more or less eﬃcient silver coordination sites.
Indeed, for the tripeptides containing strongly coordinating
amino acids such as histidine and cysteine they observed no
AgNP formation, for peptides containing weakly coordinating
amino acids, for example, lysine or aspartic acid the
mineralization of silver was slow, while it was fast for
noninteracting amino acid containing peptides such as
glycine.108 From these results, it was concluded that the
complex has to be broken prior to silver reduction by tyrosine.
Interestingly, these results imply that cysteine is a better ligand
for Ag(I) than lysine, which is not in agreement with the
calculated binding aﬃnities discussed previously in section 2.1.1
(see Table 1). A similar system was investigated by Belser et
al.118 who observed that a tripeptide containing both tyrosine
and histidine as a strong silver binder is able to mineralize silver
only after irradiation. The above summarized results for the
involvement of tyrosine in the reduction process of silver clearly
indicate that there is still a long way to go to understand the
mechanistic pathways involved in the mineralization of silver,
and it has to be seen whether the formation of dityrosine takes
place in response to the presence of silver ions.
The Role of Aspartic and Glutamic Acid. Besides Tyr, Xie
et al.108 identiﬁed Asp and/or Glu residues as key players in the
peptide-mediated silver mineralization with regard to the shape
of the formed particles. They found that their carboxyl groups
present in the side chain are promoting the anisotropic growth
and therefore dictating the shape of the formed nanostructures.
This is based on an experiment where all of the carboxylic
groups of the algal proteins were converted into amides,
yielding predominantly spherical nanoparticles or irregularly
shaped structures upon incubation with silver nitrate instead of
triangular plates, which were found before.108 The role of
glutamic acid was studied in greater detail by Fischer and co-
workers120 who explored the eﬀect of the peptide chain length
of oligopeptides (Glu)n on the crystal growth of calcium oxalate
and showed a dependence of the crystal morphology, phase,
and stability on the peptide chain length. Nam et al.121
proposed that the amino acids with carboxylic side chains are
also important for the reduction of Ag(I) by means of peptides
in combination with ambient light. They postulated a
mechanism for AgNP synthesis using engineered yeast
decorated with hexaglutamic or hexaaspartic acid in which the
coordination of silver ions by the carboxylic groups is supposed
to lower the energy barrier for their reduction.121 This is at ﬁrst
glance contradictory to the results of Xie et al.108 discussed
above where the complexation slowed the rate of AgNP
formation, hence having a negative eﬀect on the silver
reduction. Nam and co-workers121 argued that the enhanced
reducibility of silver ions due to the complexation with carboxyl
groups is probably a cooperative eﬀect. The complexation
lowers the energy barrier for the reduction as compared to an
unbound silver ion (see Table 3), which should be considered
as starting point. In case of the hexaglutamic acid derivative, the
pocket-like structure of the peptide leads to an increased local
concentration of silver ions, which is also beneﬁcial for the
reduction process. Furthermore, the Fermi level of the silver
cluster is lowered due to the electron donation of the
nucleophilic carboxyl group (Figure 8),119 thus rendering the
further reduction of Ag(I) more facile.121
Recently, Roy and Banerjee122 reported that Fmoc-protected
phenylalanine forms a stable hydrogel capable of reducing silver
spontaneously in the presence of light, forming Ag4 nano-
clusters. Their formation is ascribed to the complexation of
Ag(I) via the C-terminal carboxylic acid together with the
presence of light, which is similar to the above-described role of
glutamic and aspartic acid. The latter has a large Stokes shift
together with a narrow emission band, emitting red light, which
might be interesting for the application in sensors.122 Also,
Adhikari and Banerjee123 reported that in a short peptide-based
hydrogel, the light-induced formation of silver nanowires is
possible due to the combination of a carboxylic acid-containing
peptide (Fmoc-Val-Asp-OH) and sunlight.123 These observa-
tions are in agreement with the results reported by Belser et
al.118 who showed that a tetrapeptide containing Asp and Ser
linked by a rigid linker that does not spontaneously form
AgNPs upon incubation with silver nitrate is able to mineralize
silver only in the presence of light. The suggested inﬂuence of
the complexation with a peptide on the redox potential of silver
is discussed controversially since the work of Carter et al.124
showed that the silver redox potential does not change in the
presence of a glutamate hexamer. Nam and co-workers121
showed as well that silver nanowires can be produced through
spontaneous photoreduction working with a modiﬁed M13
bacteriophage called E4 because it has tetraglutamate (EEEE)
fused to the N-terminus of each major coat protein (p8). The
M13 bacteriophage is one of the viruses commonly used in the
phage display technique described above whose coat consists of
about 2700 copies of the 50 amino acid long p8. The so-
obtained silver nanowires were further tested for their
electrochemical behavior toward the use as anode in lithium
ions batteries, serving as model system at the nano scale.125 For
amino acids with side chains containing carboxylic acids, it can
be concluded that they function as a complexation site for silver
while their involvement in the silver reduction is discussed
controversially. Nevertheless, a lot of work has to be done to
achieve a better understanding and to allow for predictable
shapes of the formed AgNPs.
The Role of Tryptophan. Like tyrosine, tryptophan is known
to be important in biological electron transfer reactions
involving DNA photolyase, ribonucleotide reductase, or
azurin.126 Mandal and co-workers127 showed that tryptophan-
containing peptides can indeed function as reducing agent for
the formation of silver as well as gold nanoparticles. Similar to
the work on tyrosine-containing peptides,115 they proposed a
reaction under alkaline conditions, where the indole NH group
is deprotonated (16), and the neutral tryptophyl radical (17) is
formed as an intermediate, which can either dimerize to yield
ditryptophan (19), reverse back to its native form, or form the
kynurenine form (18) of the peptide (Figure 9). Kynurenine, a
known metabolite of tryptophan, and ditryptophan are both
highly ﬂuorescent, which was useful for their detection during
the nanoparticle formation.127 More evidence for the reducing
power of tryptophan with regard to metal particle formation
Figure 8. Inﬂuence of coordination of carboxylic acids on the Fermi
potential of silver clusters.
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can be obtained looking at the formation of gold nanoparticles,
where the oxidative polymerization of tryptophan was reported
during nanoparticle formation.128
Other evidence for the importance of tryptophan was given
by Carter et al.124 who investigated the silver mineralizing
properties of a peptide previously isolated from a phage library
designed for the evaluation of germania (germanium oxide)
binders,129 which was therefore named Ge8. The formation of
AgNPs with the help of these peptides additionally needed the
presence of light and 2-[4-(2-hydroxyethyl)piperazin-1-yl]-
ethanesulfonic acid (HEPES) buﬀer because the formation of
H2O2 as one involved reducing agent is accomplished via a
photoinduced decomposition of the buﬀer. In addition to the
photochemically formed reducing agent, the primary sequence
of the peptide has an inﬂuence on the reduction process.
Mutation experiments, where tryptophan or methionine, which,
as sulfur-containing amino acid, can interact with silver ions as
well, were exchanged against alanine, implement that both
amino acids are necessary in case of Ge8 for silver reduction.124
In contrast, the exchange of histidine versus alanine results in
the loss of silver ion aﬃnity, but interestingly the formation of
AgNPs is still possible with these mutants.124 In case of the
Ge8, the peptide alone apparently cannot provide suﬃcient
reducing power because a second reducing agent (H2O2) is
needed but seems to be more than just a scaﬀold for the shape
control of the formed particles. The role of tryptophan in the
particle growth of AgNPs was recently investigated by Kulesza
et al.130 who proposed the doubly charged silver cluster Ag4
2+
stabilized by tryptophan as an optical marker for particle
growth due to its characteristic absorption spectrum. The
possibility to monitor early stages of the AgNP growth might
provide further insight into this process.
The Role of Sulfur-Containing Amino Acids. Even though
tyrosine and tryptophan are discussed as the main reaction
partners responsible for silver reduction, the participation of the
two sulfur-containing amino acids cysteine and methionine
cannot be ruled out completely. As brieﬂy mentioned in the
case of the Ge8 peptide, methionine is discussed to take part in
the silver reduction process because mutants where this amino
acids are substituted with alanine were not able to produce
AgNPs.124 However, so far there is no experimental evidence
whether this amino acid really serves as electron donor or has a
diﬀerent function in the complex procedure. Interestingly,
cysteine alone was recently reported to be able to reduce silver
ions in the presence of cetyltrimethylammonium bromide
micelles.131 As mechanism, the formation of a silver-cysteine
complex is proposed that is then able to reduce free silver ions
and leads to the formation of a cysteyl radical. The micelle is
thought to stabilize the substrate and the resulting complex and
might in addition inﬂuence physical properties of the
reactants.131 That the formation of a cysteyl radical is involved
is underlined by the fact that at higher cysteine concentration
the formation of a cystine silver complex was observed.131
Because the presence of micelles is needed for the silver
reduction as well, we would not in general classify cysteine as a
reducing amino acid by itself as is the case for tyrosine or
tryptophan.
The Role of the Peptide Backbone and the Eﬀect of Silver
on the Secondary Structure. After having discussed the role of
certain amino acid side chains in the AgNP formation by means
of peptides, we will now brieﬂy focus on the amide functional
groups present in the peptide backbone because there is also
some evidence that these groups are involved in the
mineralization process as well. In general, it is known that
the binding of peptides and proteins to nanoparticles can also
occur over free amide groups, one of the main interactions
between peptides and growing silver particles besides thioether
bonding and interaction via benzyl groups of the peptides.132 Li
et al.133 were the ﬁrst to use a plant extract (Capsicum annum
L.) at room temperature for the green synthesis of AgNPs.
They assigned its reducing capability to the amide groups of the
proteins present in the plant extract. Unfortunately, this
hypothesis is only underlined by IR and electrochemical data.
In the IR, the plane bending vibration of the NH-group in
proteins is absent after silver reduction, indicating a relation
between silver reduction and oxidation of the amide functions,
while an oxidation peak present in the cyclic voltammogram of
the plant extract shows its possible reducing power.133 Another
example where the amides are believed to be responsible for
silver reduction are the cyclic peptides curcacycline A134 and
B135 (Figure 10), the major components in the latex of Jatropa
curcas, which can be used for the generation of AgNPs as
well.136,137
Beside the role of the amide, Li et al.133 also investigated the
inﬂuence of the redox process on the secondary structure of the
peptide reporting a conformational disorder upon silver
reduction because the percentage of α-helix present in the
structure decreased after the reaction. The same tendency of
increased structural disorder was recently reported by Sanghi
and Verma138 for the interaction of Ag(I) with fungal
Figure 9. Possible oxidation pathways of tyrosine lead to the formation
of kynurenine (18) and ditryptophan (19).
Figure 10. The two cyclopeptides curcacycline A and B are the major
components of the latex of J. curcas.
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mycelium. The inﬂuence of the secondary structure on the
formation of silver nanostructures was shortly discussed before
for the algal proteins examined by Xie et al.,108 which provided
nanoplates with a diﬀerent size upon denaturation of the
proteins as compared to the nanoplates formed by the folded
proteins. The change in the secondary structure seemed also to
be one of the main factors involved in the AgNP synthesis
catalyzed by the hen egg lysozyme, recently reported by Eby et
al.139 A change of the solvent from water to methanol made the
controlled growth of stable nanoparticles possible. While in
water, silver was reduced by the native lysozyme, but colloidal
stability could not be achieved, and in methanol, where the
enzyme is denaturized, stable colloids were formed, which
retained their stability to a high degree after dialysis into
water.139 The use of lysozyme for the generation of AgNPs can
also be important for medical applications because lysozome is
an inhibitor of Gram-positive bacterial strains while AgNPs are
active against both Gram-negative and Gram-positive strains.
Indeed, Eby and co-workers140 introduced a system using the
antibacterial activity of both lysozyme and AgNPs as possible
coating for medical instruments (see section 4.1.5).
Conclusion. Having discussed diﬀerent key factors involved
in the reduction of Ag(I) by means of peptides and proteins,
one bottom line is that even though huge eﬀort has been
undertaken to understand the mechanism behind this
fascinating mineralization process, there is still a lot of work
to be done to achieve a detailed insight into the mechanistic
action. One of the current models is the concept of (i)
recognition, (ii) reduction, (iii) limited nucleation, and ﬁnally
(iv) growth of the silver particles.141 As demonstrated above,
the interaction of peptides and proteins with silver seems to be
important in all phases of the mineralization process, leading to
numerous factors inﬂuencing the outcome of the reaction. With
some of the amino acids such as Tyr and Trp being important
for the reduction process, other groups such as amides or
thioether containing residues seem to play a major role in terms
of particle growth, while the amino acids with side chains
containing carboxyl groups (Asp and Glu) are responsible for
the silver coordination and nucleation and might be involved in
the silver reduction process. One of the challenges to gain a
better understanding of this multifunctional process is the
diﬃcult comparability and interpretation of the results present
in the literature due to the use of peptides diﬀering in length,
structure, composition, polarity, and so on or, even more
complicated, the use of extracts of natural products where a
mixture of compounds is most likely involved in the formation
of silver nanostructures. While the material scientists are more
interested in the silver nanostructures, the fate of the oxidized
peptides remains often unclear. This might however be of
importance for the understanding of the biological activity of
silver.
2.3.2. Peptides as Structure-Determining Scaﬀolds in
the Synthesis of Silver Nanostructures. Peptides are
known for their structural variety due to their ability to arrange
the amino acids in secondary structural elements (helices, β-
sheets, and turns) that in turn can form superior three-
dimensional arrangements. Because these structures are of a
deﬁned nature, they are good templates for the synthesis of
materials of an ordered size and shape as they are capable of
limiting the growth, preventing agglomeration, and organizing
the AgNPs. Therefore, it is not surprising that they serve as the
major biological scaﬀold material.142 The template eﬀect is also
used for the synthesis of diﬀerent complex silver nanostructures
as it will be shown in the following part on recent reports found
in the literature. An array of AgNPs can for example be
achieved using a self-assembled polymer−peptide conjugate as
a matrix for the controlled particle growth.143 A poly(ethylene
oxide)−peptide conjugate is reported to form stable double-
tape constructs with a peptidic core consisting of β-sheets and a
polymeric shell. These double-tapes stack together to ﬁnally
form two-dimensional networks. The AgNPs are located in the
peptidic core and are formed either upon irradiation of an
Ag(I)-containing solution or upon incorporation of preformed
silver nanoclusters that aggregate in a controlled fashion inside
the double-tapes.143 A second type of nanostructures obtained
by using peptides as a structure-determining scaﬀold are metal
nanowires, which are important for the development of new
nanoelectronic materials. Gazit and co-workers144 showed that
already small Phe-Phe dipeptides (20) derived from the β-
amyloid polypeptide can be suﬃcient to self-assemble into
peptide nanotubes, which can be used as scaﬀold for the
synthesis of silver nanowires through reduction of the enclosed
Ag(I) with sodium citrate. Subsequent enzymatic degradation
of the peptidic template releases the metal nanowire (Figure
11). Instead of degrading the template, the reduced silver-ﬁlled
nanotubes can also be used for the synthesis of coaxial
nanowires with a silver core and a gold outer shell. In this case,
the intact peptidic template is decorated with a second peptide,
functioning as a linker for the attachment of gold nanoparticles.
These particles are used in the last step as nucleation sites for
the gold deposition yielding a complex nanostructure with a
coaxial geometry that might be used in nanotechnology.145 A
third common target structure in nanochemistry are metal
nanotubes. Bale et al.146 attached AgNPs to poly-L-lysine (PLL)
or bovine serum albumin (BSA) functionalized multiwalled
carbon nanotubes. After a 1-day exposure to a Ag(I)-containing
solution, the tubes were washed and the reduction of Ag(I) was
accomplished using sodium borohydride leading to the
formation of AgNPs on the surface of the nanotube. They
also observed that the nanoparticle formation is hindered if the
attached protein is glycosylated. These results indicated that the
glycosylation state of proteins might be useful for the
patterning of nanostructures.146 The same approach was also
successful using active enzymes for the linkage between
nanotube and nanoparticle yielding a multifunctional nano-
composite with the enzyme still being active.146
Peptides cannot only form ordered nanosized structures as
just shown on some examples, but they are also able to form
macroscopic assemblies such as hydrogels, which are well
Figure 11. Schematic representation of the formation of silver
nanowires using peptide nanotubes consisting of Phe-Phe dipeptides
(20) as degradable template.
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ordered on the nanometer scale. Taubert and co-workers132
reported the use of an organogel consisting of oligo-L-valine
and a sulfur-containing peptide for the mineralization of silver
using dimethylformamide as a reducing agent. The size and
shape of the resulting AgNPs could be controlled by the ratio of
the two gel-forming peptides, which is accompanied by the
variation of the thiol to metal ratio demonstrating that the
Brust−Schiﬀrin concept147 in which the size depends on the
thiol amount is transferable to rather stiﬀ supramolecular
assemblies.132 Oligovaline does not react with the formed
AgNPs but is important for the gel formation, while the thiol-
containing peptide is necessary for silver coordination,
nucleation, and organization.
Taubert and co-workers148 recently published an elaborate
study on the inﬂuence of the peptide on the properties of the
mineralized material, using the hexapeptide (Lys-Lys-Cys)2 in
which the two subunits are dimerized via a disulﬁde linkage of
the cysteine side chains. There has been strong evidence that
the pH inﬂuences the aggregate formation of peptide-coated
AgNPs due to diﬀerent patterns of protonation/deprotonation
with regard to the termini and the side chains of the amino
acids. At low pH, the hexapeptide was able to stabilize
individual particles predominantly through interaction of the
sulfur atoms with the AgNPs, while at high pH the formation of
larger aggregates was observed, which might lower electrostatic
repulsion with the lysine moieties being deprotonated.148,149
This aggregate formation, however, was reversible upon
lowering the pH of the solution. They could further show
that the obtained peptide-coated AgNPs can be coated with a
silica shell retaining the chiral information carried by the coated
AgNPs149 and that the incorporation of erbium into this shell
leads to the formation of paramagnetic and chiral AgNPs.150
Recently, Upert et al.151 reported the use of oligoprolines as
scaﬀolds for the size-controlled formation of AgNPs with the
diameter of the AgNPs correlating with the length of the
aldehyde-functionalized helical peptides. The aldehyde func-
tions are used in a Tollens reaction to reduce the silver ions to
AgNPs that are stabilized by the resulting carboxylic acids.
Thus, the side-chain modiﬁcation of peptides can oﬀer
additional possibilities to control the growth of AgNPs.
In this section, it was shown that peptides act as excellent
scaﬀolds for the controlled synthesis of silver nanostructures,
enabling the directed generation of, for example, nanotubes,
nanowires, and arrays of nanoparticles. These nanostructures
are interesting for technical and medical applications. Examples
for the use of silver nanostructures in the construction of new
materials will be discussed in section 4, while the biocompat-
ibility of silver and silver-functionalized materials will be
reviewed in section 5. Prior to this, the following section will
focus on the interaction of bacteria with silver. As indicated
above, this interaction is not only important for the synthesis of
AgNPs but also for the understanding of the antimicrobial
activity of silver compounds.
3. BACTERIA AND SILVER
3.1. Antimicrobial Properties of Silver-Containing
Compounds
It has been known for a long time that silver cations are highly
toxic to bacterial cells.152−154 AgNO3, for instance, shows an
antimicrobial activity with a minimal inhibitory concentration
(MIC) of 3 μM (323 μg L−1)155 against a silver-sensitive E. coli
strain. Although silver cations have found extensive applications
in various ﬁelds of industry and medicine (see sections 4 and
5), silver in its oxidation state zero has recently been of
increasing interest as well. AgNPs have gained considerable
attention over the last few decades in response to the raising
need for antimicrobial compounds due to the increasing
bacterial resistance to commonly used antibiotics. Because of
their small size, nanoparticles possess new chemical, physical,
and biological properties distinctive from those oﬀered by
traditional bulk materials.156 The particle size exhibits the
general tendency that a smaller particle size results in a greater
antimicrobial eﬀect. This is related to the available surface area
per unit mass,157,158 which allows a higher silver ion release and
an easier interaction with other particles.159 Correspondingly,
the formation of aggregates, leading to a reduced accessible
surface area and thus reduced silver ion release, is probably
responsible for a decreased antimicrobial activity.160 The
investigation of the antimicrobial properties of AgNPs started
at the beginning of the millennium,152 and they have since
demonstrated their broad range of antimicrobial activity against
Gram-pos i t i ve as we l l a s Gram-negat ive bacte -
ria,152,157,158,161−166 fungi,163,164,166 and viruses.167−173
Silver compounds are reported to exhibit multidirectional
activity to ﬁght bacteria ultimately leading to cell death.
Therefore, several attempts have been made to elucidate their
mode of action.152,162,166,174,175 Some aspects of the anti-
bacterial eﬀect of silver nanomaterials were recently reviewed
by Mariambio-Jones and Hoek.176 However, until present days,
a complete understanding of the mechanism of silver ions and
AgNPs ﬁghting bacteria has not been reached. Nevertheless,
there are several pathways known for the interactions between
silver compounds and the bacterial cells.176 These interactions
can be classiﬁed as direct interactions of the silver compounds
with (i) the bacterial cell wall, (ii) DNA, (iii) enzymes and
membrane proteins, and (iv) as interactions based on the silver-
induced formation of reactive oxygen species (ROS). The
interaction pathways are summarized in Figure 12 and will be
discussed in more detail in the following. In addition, we will
brieﬂy focus on physical properties of AgNPs inﬂuencing their
antimicrobial activity.
3.1.1. Interactions with the Bacterial Cell Wall. As
shown in Figure 12, the interaction with the bacterial cell wall is
one of the ﬁrst points of attack and important for the
Figure 12. Possible interaction pathways of silver-containing
compounds with bacterial cells: Direct interaction with (i) the cell
wall, (ii) DNA, (iii) membrane proteins, and (iv) formation of ROS.
Adapted with permission from ref 176. Copyright 2010 Springer
Science and Business Media.
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antimicrobial activity because (i) the crossing of the plasma
membrane allows silver compounds to interfere with the
bacterial DNA located in the cytoplasm or to generate ROS in
the interior of the cell (this will be discussed in the following
subsections), and (ii) the accumulation of silver in the cell
membrane aﬀects its permeability,176 which can cause the
leakage of the cytoplasm leading to cell death. Before discussing
the interaction with the cell wall of bacteria, one should keep in
mind that the bacteria are classiﬁed into two main groups
depending on their cell wall structure. For Gram-positive
bacteria, the cell wall consists of a thick peptidoglycan layer
(15−80 nm),177 a polymer consisting of sugars and amino acids
that forms a mesh-like structure on the outside of the plasma
membrane. In addition, polyalcohols, so-called teichoic acids,
are found in their cell wall providing additional stability. The
peptidoglycan layer of Gram-negative bacteria on the outside of
the plasma membrane is much thinner than that for Gram-
positive bacteria (∼2 nm),177 but they have an additional outer
membrane composed of phospholipids and lipopolysaccharides
around the peptidoglycan layer.
Using TEM, it has been shown that the direct interference of
Ag(I) with bacterial cells causes morphological changes of their
cell wall resulting in the detachment of the plasma
membrane.175,178 Silver ions, for example, caused the lysis of
Staphylococcus aureus (S. aureus) and E. coli cells by detaching
the cell membrane from the cell wall resulting in the leakage of
the cellular interior. On the TEM image, the presence of
electron-rich silver-containing granules in the surrounding of
the cell was observed, which is a clear indication for the
interaction of silver ions with the plasma membrane. The
observed eﬀect was greater in case of Gram-negative E. coli than
for Gram-positive S. aureus, which can be attributed to the
above-described structural diﬀerences in their cell wall with the
thick peptidoglycan layer protecting the plasma mem-
brane.175,178
A similar inhibition trend was observed for the use of AgNPs
as active silver compound. The particles attach to the plasma
membrane, change its permeability, disequilibrate the adeno-
sine triphosphate pool and the proton motive force, and ﬁnally
lead to cell death.152,161 However, there is also evidence that
the adhesion of AgNPs to the cell wall does not necessarily lead
to its disruption as, for instance, Choi et al.179 did not observe
any plasma membrane leakage due to the presence of AgNPs.
These diﬀerent observations might be due to a variety of
reasons such as diﬀerent bacterial strains, AgNP concentration,
size, shape, surface charge/functionalization (see below), or
analytical methods.
Despite the tendency that the higher the concentration of
AgNPs, the larger the inhibitory eﬀect, regardless of the type of
microorganism,152,166,180 Kim et al.166 recently showed that
Gram-positive S. aureus was less susceptible to the presence of
AgNPs than Gram-negative E. coli. For further explanation, one
should bear in mind that AgNPs are not necessarily neutral
particles, as their surface can be positively or negatively charged
due to the presence of stabilizing agents or additional surface
modiﬁcations.166,181,182 This surface charge is important in
terms of electrostatic interactions with the bacterial cell wall
and is reﬂected by the zeta potential. One should expect that
positively charged AgNPs are attracted by negatively charged
lipopolysaccharides present in the outer membrane of Gram-
negative bacteria, thus facilitating the interaction with the
plasma membrane and enhancing the antimicrobial properties
of AgNPs toward Gram-negative bacteria.183 In contrast, a thick
rigid layer of peptidoglycan is, on the one hand, harder to
penetrate and oﬀers, on the other hand, only a limited number
of anchoring sites for AgNPs, rendering their attack more
diﬃcult.183 The importance of the surface charge on the toxicity
of AgNPs was conﬁrmed by coating nanoparticles with citrate
(citrate-AgNPs) and branched poly(ethyleneimine) (BPEI-
AgNPs). An antimicrobial assay was then carried out on Gram-
positive bacillus strains possessing a net negative charge on the
membrane,181,184 which showed that there is a direct
correlation between the surface charge and the antimicrobial
activity of the nanoparticles. In this assay, the negatively
charged citrate-AgNPs were much less toxic than the positively
charged BPEI-AgNPs due to higher repulsive interactions
between negatively charged NPs and the similarly charged
membrane of the bacillus cells.181
Another possible mechanism for the integration or even
penetration of AgNPs through the bacterial cell wall is the
formation of breaks, so-called pits. The pit formation has
recently been illustrated for Gram-negative165 and Gram-
positive185 bacteria using TEM. The proposed mechanism for
the cell wall interaction and pit formation is depicted as
proposed by Mirzajani et al.185 in Figure 13. It is suggested that
the AgNPs destroy the β−1→4 glycosidic bonds that connect
the building blocks of the peptidoglycan N-acetylglucosamine
and N-acetylmuramic acid. This would ﬁnally lead to the release
of these building blocks into the media. Indeed, the authors
found an increased concentration of muramic acid in the media
when AgNPs were present.185 Besides, it was shown by CD
spectroscopy that the structure of the peptide branch was
Figure 13. Depiction of the silver interaction with the bacterial cell
wall leading to cell wall-damaging pit formation. Adapeted from ref
185. Copyright 2011 Institut Pasteur, published by Elsevier Masson
SAS.
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altered upon addition of AgNPs. Both ﬁndings underline the
proposed mechanism experimentally.
Because both silver ions and AgNPs show a related behavior
toward the cell wall,161 there is still an ongoing discussion on
how much this antimicrobial activity of AgNPs can be ascribed
to the release of Ag(I).166,186,187 It is even discussed in the
literature that the release of Ag(I) is the only reason that has to
be taken into account for the antimicrobial activity of AgNPs
and that these particles can therefore utterly be considered as a
silver ion reservoir155 or as modern Trojan horse188,189 that
facilitates the release of silver ions inside the cell. There is
experimental evidence for the release of ionic silver from
AgNPs because the amount of free silver ions in solution can be
measured.155,179 Several possible mechanisms for this Ag(I)
release are discussed in the scientiﬁc literature. Choi et al.179
proposed an oxygen-mediated oxidative dissolution process
according to eq 1:
+ + → ++ −4Ag O 2H O 4Ag 4OH2 2 (1)
This theory is underlined by Liu and Hurt190 who indeed
observed an increase of the pH upon AgNP dissolution.
Further on, their thermodynamic analysis predicts citrate-
AgNPs to be unstable under aerobic biological conditions.
Concerning the mechanism of silver ion release, they proposed
a stepwise reduction of oxygen to water via peroxide
intermediates rather than a four-electron transfer process.
However, ﬁrst results indicated that this oxidation process is
slow, allowing the participation of other interaction path-
ways.190 Xiu et al.191 in this context postulate the formation of
Ag2O-NPs that are then able to release silver ions. Lok et al.
155
indeed found experimental evidence that the formation of
partially oxidized NPs is involved in their antimicrobial activity
because only the Ag2O-NPs exhibited antimicrobial activity
against E. coli cells but not their precursor AgNPs synthesized
by borohydride reduction of AgNO3.
Another release mechanism was hypothesized by Marambio-
Jones and Hoek176 who suggested that the mechanism,
proposed by Asharani et al.192 to take place in the mitochondria
of eukaryotic cells (eq 2), could take place in bacterial cells as
well.
+ + → ++ +2Ag H O 2H 2Ag 2H O2 2 2 (2)
Liu et al.193 recently compared AgNPs to drug delivery
systems, with the NP being the silver ion deliverer. They
admitted however that a tuning of the release of the ionic silver
is needed to improve current nanosilver technologies. Possible
chemical approaches for a controlled release, in addition to the
previously discussed primary release by oxidative dissolution,
might be (i) inhibition by an insoluble Ag2S ﬁlm (Ksp = 6× 10
−51
mol3 L−3)194 on the NP surface, (ii) surface passivation, (iii)
preoxidation, (iv) polymeric coatings, or (v) the reversible
surface binding of silver ions.193 Indeed, their ﬁrst results
showed that the inhibition of the bacterial growth is higher for
preoxidized AgNPs than for untreated AgNPs, an observation
that is in agreement with the above presented results of Lok et
al.,155 while AgNPs functionalized with 11-mercaptoundecanoid
acid showed a much slower silver ion release as compared to
the untreated samples. Recently, it was shown as well that
AgNPs are transformed in wastewater treatment plants either
completely into less toxic Ag2S-NPs or into core−shell particles
consisting of a Ag core and a passivating Ag2S shell.
195 In
general, it has been shown that the toxicity of both silver ions
and AgNPs is inﬂuenced by the presence of silver coordinating
counterions such as the appearance of common negatively
charged ions, such as Cl−, SO4
2−, S2−, and PO4
3−. Their
interaction with Ag(I) may cause its complexation and,
depending on the concentration, also its precipitation, both
leading to the further reduction of its bioavailability and toxicity
(see also Figure 25, section 5.5).196−198 Recently, the
correlation between the presence of common ligands versus
antimicrobial activity of AgNPs and Ag(I) was investigated in
vitro.191 It was found that the antimicrobial activity of AgNPs
was less aﬀected than the one of Ag(I) by the exposure to Cl−
under anaerobic conditions resulting in a drop in activity of 9%
and 55%, respectively.191
In summary, both silver ions and AgNPs are able to interact
with the cell wall, which is one reason for their antimicrobial
activity. However, concerning the toxicity of AgNPs, there is
still some evidence needed to precisely answer the question on
how much their antimicrobial activity depends on the release of
ionic silver. It is widely accepted that the silver ion release is an
important mechanism in terms of AgNP toxicity, but as section
3.1.3 will show, it does not seem to be the only mechanism
involved.
3.1.2. Interactions with DNA, Enzymes, and Mem-
brane Proteins. The interaction with the cell wall oﬀers to the
silver-containing species the possibility to penetrate the cell and
to interact with compounds in its interior such as DNA or
enzymes. Holt and Bard199 were able to determine the silver
ion uptake by immobilized E. coli cells (1 μM AgNO3, 107.9
μg L−1) resulting in a transport of 60% of the ionic silver inside
the cell, while 40% remained bound to the outside of the cell
without passing the plasma membrane. As was already
mentioned in the previous subsection, silver ions caused the
lysis of E. coli and S. aureus cells leading to a leakage of the
cellular interior.175 Besides the detachment of the cell
membrane from the cell wall, the TEM image showed an
electron-light region in the center of the cell that was assigned
to densely packed, so-called condensed DNA, which thereby
loses its ability to replicate.175 This region is well separated
from the electron-dense granules that contained a signiﬁcant
amount of silver and sulfur according to X-ray microanalysis,
and it is surrounded by an electron-rich region.175 Thus, this is
a clear indication for the interaction of silver ions with DNA. A
similar observation was made for AgNPs when Li et al.162
concluded from TEM images the presence of condensed DNA
in the cytoplasm of Gram-positive S. aureus cells treated with a
commercially available AgNP solution (pH 7).
On a molecular level, Arakawa et al.200 identiﬁed guanine N7
and adenine N7 as the preferential binding site of Ag(I) in
DNA by FTIR spectroscopy and capillary electrophoreses.
Ag(I) has also been used for the construction of metal-
mediated base pairs. Recently, Johannsen et al.201 used artiﬁcial
imidazole-Ag(I)-imidazole base pairs, as conﬁrmed by NMR
spectroscopy, for the construction of a DNA double-helix in
which the metal ions are located along the helix axis without
major conformational distortion of the helix. It is suggested that
this artiﬁcial motive might be used in the future as recognition
site.201
Once inside the cell, silver compounds do not only interact
with DNA, but with a number of enzymes as well. Li et al.162
found that AgNPs in contact with Gram-positive S. aureus
inhibit the cell respiration and inﬂuence the expression of
certain enzymes. It was shown that the enzymatic activity of the
respiratory chain dehydrogenase decreased with increasing
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AgNP concentration.162 A similar proportional correlation
between the AgNP concentration and the enzymatic activity of
the respiratory chain dehydrogenase has been reported for
Gram-negative E. coli cells treated with AgNPs.165 Also, for the
mitochondrial respiratory chain such kind of interference has
been observed. In this case, a reduced dehydrogenase activity
was induced by the presence of AgNPs, which could be
measured by the reduction of resazurin to resofurin (Figure
14).192 This reduction is performed only by vital cells leading to
a color change from blue to pink (CellTiter Blue viability
assay).
Silver ions can interfere with enzymes by binding to their
amino acids forming silver−amino acid complexes (see section
2.1), which can also lead to the replacement of the native metal
cation from its binding site in the enzyme. That Ag(I) is able to
displace Cu(I) has, for example, been shown for ethylene
receptors found in plants, where this metal ion exchange leads
to the blocking of the ethylene perception.202 It has been
reported that, for the interaction between silver ions and
proteins, the silver binding to thiol groups, present, for instance,
in the amino acid side chain of cysteine, is thought to be
essential and leads to the inactivation of the enzyme.203−205 As
was already discussed above, one should keep in mind that
other amino acids should be much better ligands for silver ions
based on their theoretically (Table 1) and experimentally
determined silver ion aﬃnities, and therefore this interaction
might be overestimated if there are other amino acids with high
silver ion aﬃnity around such as arginine or histidine. However,
the importance of the binding of silver toward cysteine has
been shown, for example, by the destruction of an iron−sulfur
cluster, a cofactor involved in many enzymatic reactions, due to
the presence of Ag(I).206,207 For the enzyme fumarase A, a
member of the dehydratase family, it has recently been
demonstrated in vitro using E. coli cells that the enzyme is
inhibited due to the destruction of the cofactor.206 Besides, Kim
et al.208 showed that silver ions are more eﬀective antimicrobial
agents against E. coli when the probably formed silver−cysteine
complex is irradiated with ultraviolet-A light. Spectrophoto-
metric and MALDI-TOF mass analyses revealed that the
photochemical reaction of this silver−cysteine complex and the
associated formation of monosulﬁde radicals are one of the key
factors in the light-induced enhancement of the antimicrobial
properties of silver ions. One of the most prominent examples
for the interaction of silver ions with thiol groups in enzymes is
the reduced nicotinamide−adenine dinucleotide (NADH)
dehydrogenase. The direct eﬀect of silver ions on the
respiratory chain was ﬁrst discovered 1974 by Bragg.209 A
consequence of this interaction is the decoupling of the
bacterial respiratory chain from the proton motive force across
the plasma membrane, which results in the positive stimulation
of the respiration before cell death. Holt and Bart199 were able
to demonstrate this relation for E. coli. Presumably, the ﬁrst
experimental evidence for the silver-related collapse of the
proton motive force has been given by Dibrov et al.210 and has
been explained by the binding of Ag(I) to membrane proteins.
It has been shown on the example of Vibrio cholera that the
presence of silver ions at low (micromolar) concentrations is
responsible for the leakage of protons through the cell
membrane resulting in the collapse of the proton motive force.
The silver binding to NADH dehydrogenase also leads to the
production of large quantities of ROS, which might be an
explanation for the toxicity of silver ions to E. coli already at
submicromolar concentrations.199 The participation of ROS in
the toxicity of silver-containing compounds will be discussed in
more detail in the following subsection.
3.1.3. Generation of Reactive Oxygen Species. The
role of ROS in the antimicrobial properties of silver compounds
has already been indicated above and has been depicted in
Figure 12. The most important ROS discussed in this context
are singlet oxygen, hydrogen peroxide, superoxide radical anion,
and hydroxyl radical.211,212 They are known to target mainly
lipids, DNA, RNA, and proteins, causing severe consequences
such as the malfunction of membranes, proteins, and the DNA
replication machinery.212 Because ROS are continuously
produced from molecular oxygen as a byproduct during the
metabolism of cells grown under aerobic conditions (eq 3),
protective mechanisms were developed by these organ-
isms.212,213
→ ⎯ →⎯⎯⎯⎯⎯⎯⎯ → + ⎯ →⎯⎯⎯⎯⎯⎯⎯− + − · +
− − + − − +
O O H O OH OH 2H O2
e
2
e 2H
2 2
e e 2H
2
(3)
This protection is reﬂected by the presence of two sensor-
regulator proteins called SoxR and OxyR, which in “unstressed”
cells are latent. Once exposed to oxidative stress, which can be
deﬁned as the imbalance between the amount of ROS and the
cell-own defense functions, the two aforementioned proteins
become activated, hence sensing the presence of superoxide
radical anion and hydrogen peroxide, respectively.211,212 A
recent study on both Gram-negative and Gram-positive
bacterial strains by Park et al.211 showed (i) that the
antimicrobial activity of silver ions is higher under aerobic
than under anaerobic conditions and (ii) that this enhancement
is due to the formation of the superoxide radical anion, which,
based on the amount of activation of SoxR and OxyR, is more
important for the antimicrobial activity of silver ions than
hydrogen peroxide. These ﬁndings underline a study by Holt
and Bard199 who found that the formation of ROS is one
consequence of the interaction of silver ions with enzymes in
the respiratory chain (see section 3.1.2). The blocking of
respiratory chain enzymes as a ﬁrst step of an enhanced ROS
production was also discussed by Gordon et al.207 who
postulated the destruction of iron−sulfur clusters and
subsequent Fenton reaction as origin of formed hydroxyl
radicals. This hypothesis was among others supported by the
upregulation of genes encoding oxidative stress response, hence
supporting survival, for the investigated S. epidermidis, while
other genes were downregulated resulting in a general growth
arrest or an adaptive response to the presence of silver.
Figure 14. The reduction of resazurin to resofurin is only performed
in the presence of vital cells and is responsible for the color change in
the CellTiter Blue viability assay.
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Another evidence for the participation of ROS in the mode
of action of silver ions was obtained by testing the inhibitory
properties of silver loaded zeolite (Ag-Z) toward the growth of
E. coli.214 It was shown that (i) Ag-Z was active toward bacteria
only in the presence of oxygen and (ii) the presence of ROS
scavengers drastically curtailed the antibacterial activity of Ag-Z.
Both observations suggest that ROS are formed and that they
are one reason for the antimicrobial activity of the silver.
Kim et al.166 hypothesized in their work that the generation
of ROS in relation with silver is not only based on the presence
of Ag(I), be it through the addition of silver salts or their
release from AgNPs, but can be traced back directly to AgNPs.
Using EPR spectroscopy, they detected the release of free silver
radicals from AgNPs. Although the damage of the cell
membrane due to free radicals was proposed as an explanation
for the observed phenomenon, no further experimental data
were provided to underline this proposal.166 The dominant
formation of the superoxide anion in vitro, mentioned above in
the context of Ag(I), was also observed for E. coli cells treated
with AgNPs by using stress speciﬁc bioluminescent bacteria,174
indicating that the form of the silver species is of minor
importance. With regard to the diﬀerent forms of silver, the
same conclusion was drawn by Choi and Hu213 who observed
ROS formation in vitro for all of the used silver formulations
(AgNPs, ionic silver, and AgCl colloids). The possibility that
the ROS generation is induced by the presence of light is also
discussed, but only a poor correlation between the inhibitory
activity and the photocatalytic ROS concentration was
found.213
In contrast to the aforementioned studies, there are reports
claiming that the formation of ROS has only a more or less
negligible contribution to the antimicrobial properties of silver
compounds. For instance, Sintubin et al.186 detected only a
small amount of ROS in the presence of AgNPs by using a
ﬂuorescence assay based on 2′,7′-dichlorodihydroﬂuorescin
diacetate, and the formation of an even minor extent of ROS
was induced by ionic silver alone. In combination with their
other results, they came to the conclusion that ROS production
plays only a secondary role in terms of antimicrobial activity.
The contribution of ROS formation is discussed controversially
not only for AgNPs but also for Ag(I), as for example by Xiu et
al.,191 who reported that neither the presence nor the absence
of oxygen inﬂuences the antibacterial activity of Ag(I). As a
possible reason for the enhanced antimicrobial activity of
AgNPs exposed to oxygen, they suggested the enhanced silver
release rate of oxidized AgNPs, as was already mentioned in
section 3.1.1.191 These sometimes contradictory results on the
importance of ROS in terms of silver’s antimicrobial properties
clearly lead to the bottom line that there is still a lot of eﬀort to
be made to understand the mode of action.
To conclude this subsection on the antimicrobial properties
of silver compounds, there is no doubt that silver acts in a
multidirectional fashion. This complexity renders its study and
understanding rather diﬃcult because there are several factors
involved in the puzzle such as: (i) diﬀerent interaction
pathways with the bacterial cell, (ii) diﬀerent bacterial
strains,152,166 (iii) diﬀerent forms of silver present in and
outside the cell (ionic silver versus AgNPs), and (iv) the
concentration of the silver compound180,215 as well as the one
of silver coordinating ligands.191 When working with AgNPs,
several additional factors become important such as their
size,157,158,213 the presence of ligand coatings193 inﬂuencing
among others their surface charge,181 and ﬁnally even their
shape.180
Another rising issue are reports on resistant bacteria even
though one advantage of silver as antimicrobial compound is
claimed to be its broad mode of action, which should make the
resistance building rather diﬃcult.216−218 On the one hand, it
poses a threat and danger to the medical ﬁeld,219,220 but on the
other hand, it constitutes a potential for the biosynthesis of
AgNPs from an industrial point of view. The bacterial resistance
to the presence of silver is discussed in section 3.2, whereas
methods for the biosynthesis of AgNPs are described in section
3.3.
3.2. Bacterial Resistance Mechanisms against Ag(I)
The use of silver as an antimicrobial agent was abandoned in
the middle of the 20th century in response to the discovery and
development of antibiotics,221 but with the fast increase of
resistance build-up in bacteria, especially against conventional,
narrow-spectrum antibiotics, silver-based compounds enjoy
again great popularity.180 As was brieﬂy mentioned above, the
biggest advantage of silver as an antimicrobial agent originates
from its multidirectional activity. Thus, resistance development
is very diﬃcult and requires plenty of mutations in the cell.180
However, it was discovered that some bacterial strains, regularly
exposed to relatively high (millimolar) concentrations of silver,
were able to grow in this silver-rich environment.222−228 This
surprising discovery led to an intensiﬁed interest in the silver
resistance machinery. Bacterial resistance to toxic metals is in
general encoded on plasmids, but in rare cases also on the
bacterial chromosomes.229,230 In the case of silver resistance,
the most frequently discussed plasmids in the scientiﬁc
literature are pKK1,231 pUPI199,232 and pMG101,217 all
shown in Table 4.
The molecular mechanisms behind the silver resistance are
still not completely understood and currently rely on two
leading theories: The ﬁrst one is the accumulation and storage
of silver,94 and the second one is a silver eﬄux mechanism.221
Both theories are based on the same concept, which is the
detoxiﬁcation of the cell.233 The former, often controversially
discussed in the literature,10,234 predicts the accumulation of
ionic silver that is in turn transformed to less harmful
Ag(0),94,235 whereas the latter anticipates that silver ions are
transported out of the cell.10
3.2.1. Accumulation and Storage-Based Mechanism.
Having a closer look at the ﬁrst proposed mechanism, one of
the earliest investigations on the accumulation of Ag(I) is based
on the silver resistant P. stutzeri strain AG259. This strain
naturally found in the soil of silver mines was for the ﬁrst time
analyzed by Haefeli et al.236 in 1984. The presence of the pKK1
plasmid was exclusively observed in Ag-resistant colonies.
Slawson et al.154,237 revealed that the Ag-resistant (AG259) and
Table 4. Transferable Silver Resistance Plasmids
plasmid molecular weight (kb) from to way of transfer ref
pKK1 75 P. stutzeri AG259 P. putida CYM318 high voltage electrotransformation 231
pUPI199 54 Acinetobacter E. coli K12 conjugation 232
pMG101 180 Salmonella E. coli conjugation 217
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the Ag-sensitive (JM303) P. stutzeri strains were both able to
accumulate silver, but only the resistant strain was able to form
dense metal deposits as was observed using TEM and energy
dispersive X-ray analysis. Because high sulfur content was found
for the resistant strain AG259, the production of hydrogen
sulﬁde was suggested to play a role in the formation of metal
deposits that were claimed to be silver sulﬁde. Later, Klaus et
al.94 reported the formation of nanosized crystals of diverse
types (elemental silver, silver sulﬁde, undetermined composi-
tion) and shapes using the same silver-resistant strain,
indicating that already small changes in the experimental
conditions might have a huge eﬀect on the outcome of the
experiment.
As shown in Table 4, the plasmid pUIP199 has also been
discussed to be responsible for the accumulation of silver ions,
but experimental data using this plasmid are rare. It was shown
that the plasmid and, with it, the silver resistance were
transferable from Acinetobacter baumannii to E. coli and that it
did not encode for resistances against other metals or
antibiotics. However, it was not clear whether the silver was
accumulated on the surface of the cell or in its interior.232
3.2.2. Eﬄux Pump-Based Mechanism. The second
explanation for silver resistance, related to the third plasmid
pMG101, is based on an eﬄux system, which was for the ﬁrst
time postulated by Silver et al.238 in 1999. Since then, this is the
most deeply studied and most frequently cited model for silver
resistance. The research on Salmonella isolated from a hospital
burn ward revealed that the silver resistance is encoded by sil
genes located on the transferable plasmid pMG101 (Figure
15).217 This plasmid is also responsible for further resistances
against other heavy metals or antibiotics.217,223 The encoded
resistance system shown in Figure 16 consists of two Ag(I)-
binding proteins (SilE and SilF) and two diﬀerent eﬄux pumps,
which are a P-type ATPase (SilP) and a three-protein
chemiosmotic cation/proton antiporter (SilCBA). The pro-
duction of these sil-proteins only takes place if the cells are
grown in the presence of silver, and it is regulated by a system
consisting of an ATP kinase (SilS) as a membrane sensor and a
transcriptional regulatory protein (SilR) as responder. First,
extracellular signals are detected by SilS, and subsequently an
aspartate residue on SilR is trans-phosphorylated leading to the
synthesis of other sil-proteins.10 Because pumping systems as
formed by SilCBA10,11 are well investigated due to their
presence in resistance machineries against other heavy metals as
well,230,239 we will concentrate in this Review on the role of the
two Ag-binding proteins.
Although SilE and SilF are both expected to bind silver, they
diﬀer signiﬁcantly in their composition and their mode of
Figure 15. Origin of silver resistance in Salmonella. Adapted with permission from ref 10. Copyright 2006 John Wiley and Sons. Adapted with
permission from ref 11. Copyright 2006 Springer Science and Business Media.
Figure 16. Protein products of bacterial plasmid silver resistance genes. Adapted with permission from ref 10. Copyright 2006 John Wiley and Sons.
Adapted with permission from ref 11. Copyright 2006 Springer Science and Business Media.
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action.11 SilE is a small periplasmic protein consisting of 143
amino acids, which is 47% identical to the metal binding
peptide PcoE from the plasmid copper resistance system of E.
coli.217 In both proteins (SilE and PcoE), 10 histidine residues
are located on identical positions.217 SilE possesses a high
speciﬁcity for Ag(I) over Cu(II) and Cd(II),217 and the 10
histidine imidazole nitrogen atoms were determined by NMR
spectroscopy as the primary silver binding sites.10 This binding
is supposed to lead to a structural change from a random coil to
a predominantly α-helical system.10 However, to the best of our
knowledge, the publication given as reference for the structural
changes upon Ag(I) binding never appeared, so that
experimental proof is missing.
SilE, silP, and silS gene homologues were also found in a
silver-resistant Morganella strain carrying out an extracellular
biosynthesis of AgNPs (see section 3.3).216 The nucleotide
sequence of this silE homologue showed 99% similarity with
the silE found in Salmonella. Recently, the screening of 10
Morganella strains used for the production of AgNPs revealed
the presence of a silE gene homologue, thus emphasizing the
role of silver resistance genes in the production of nano-
particles.240 Contrary to earlier ﬁndings that the silE gene is
always associated with the presence of other sil genes,10 it was
present alone in two methicillin-resistant S. aureus (MRSA) and
an isolate of methicillin-resistant coagulase-negative staph-
ylococci strain.220 These bacteria were not able to survive in
the presence of silver ions for a long period of time, indicating
that the silE gene alone does not provide suﬃcient
protection.220
The second silver binding protein encoded in the sil system,
SilF, is a homologue of the chromosomal encoded241 CusF in
E. coli (50% identity).11 CusF is part of the recently reviewed242
Cus eﬄux system that removes Cu(I) and Ag(I) via a
methionine shuttle. The small periplasmic protein CusF (110
amino acids), whose crystal structure is known with243 and
without244 Ag(I), is proposed to serve as a metallochaper-
one.245 Contrary to other known metal carrier proteins, CusF
acts in form of a monomer in which three amino acids (Met47,
Met49, His36) are involved in the full coordination of Ag(I),
and Trp44 is capping the metal binding site of the molecule
potentially by a η2−π interaction.243,246 CusF has a higher
binding aﬃnity for Ag(I) than for Cu(I), which may be
ascribed, for instance, to the diﬀerent aﬃnities of those ions to
sulfur ligands or to their diﬀerent sizes. According to X-ray
absorption spectroscopy, the environment for Cu(I) is similar
to the one found for Ag(I), thus suggesting a similar binding
situation.245 The four amino acids forming the principal
binding motif are preserved in the sequence of the 96 amino
acid long SilF as shown in Table 5.247,248 Consequently, SilF is
predicted to adopt a β-sheet structure similar to CusF in which
a single histidine and two methionine residues bind the silver
cation.11 In the current models, both metal binding proteins
CusF and SilF are responsible for the capture and subsequent
transport of Ag(I) to the corresponding eﬄux pumps, where
the toxic metal ion is ﬁnally eliminated from the cell.
At a ﬁrst glance, both models explaining the silver resistance
in bacteria seem to be contradictory to each other because the
ﬁrst one involves the accumulation of the metal ion inside the
cell while the second one eliminates speciﬁcally this metal ion.
However, their authenticity might be exempliﬁed by the
bioproduction of AgNPs (discussed in detail in the following
section), where the bioaccumulation of Ag(I) leads to
intracellular synthesis,94 and the so-formed particles are
extracted by an eﬄux system.249 For a complete understanding
of the resistance machinery, a lot of open questions still remain
to be answered such as (i) whether there is a maximum Ag(I)
concentration manageable by the eﬄux pumps and the storage
system, (ii) whether the formation of AgNPs can really protect
cells considering that they are doubtlessly able to release Ag(I),
and (iii) how the resistance transfer or the occurrence of cross
resistances can be prevented. In addition, it is not clear from the
literature whether the same transporters are involved in the
metabolism of AgNPs.
3.3. Synthesis of Silver Nanoparticles by Means of Bacteria
Using the possibilities oﬀered by silver-resistant bacteria, there
has recently been a growing interest in the bioproduction of
AgNPs. The main advantages of using bacteria over traditional
chemical methods are that they generate less waste, prevent the
generation of harmful byproducts, and require less energy in
the production process. Because this manufacturing is
considered as ecologically friendly, it is often termed “green
synthesis”.158,216,250 In addition, (i) bacteria are relatively easy
to handle, (ii) the recovery and puriﬁcation (downstream
processing) of the formed AgNPs is simple, and (iii) their
genetic manipulation is straightforward allowing the tuning of
the formed NPs.216 Besides, modiﬁcations of the experimental
conditions such as the Ag(I) concentration,251,252 the bacterial
strain,253 pH of the media,94,252,253 reaction time,94 or reaction
temperature249,251,252 result in AgNPs diﬀering, for instance, in
size,94,252,253 amount,251,253 shape,249 or morphology.94
Table 5. Amino Acid Sequence of CusF and SilF247,248 a
protein amino acid sequence
CusF 10 20 30 40
MKKALQVAMF SLFTVIGFNA QANEHHHETM SEAQPQVISA
50 60 70 80
TGVVKGVDLE SKKITIHHDP IAAVNWPEMT MRFTITPQTK
90 100 110
MSEIKTGDKV AFNFVQQGNL SLLQDIKVSQ
SilF 10 20 30 40
MLKHISHGDM NAASDASVQQ VIKGTGIVKD IDMNSKKITI
50 60 70 80
SHEAIPAVGW PAMTMRFTFV NADDAINALK TGNHVDFSFI
90 INVTQS
QQGNISLLKS
aThe amino acids responsible for Ag-binding (H-histidine, M-methionine, W-tryptophan) are underlined.
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Nevertheless, several challenges are posed to the biosynthesis
of NPs such as (i) the toxicity of reactants and products for the
microorganisms themselves, (ii) the high production costs due
to sterile conditions, costly culture media, or large reaction
volumes, and (iii) the low productivity.251 However, the use of
bacteria living under extreme conditions might solve some of
these issues and has indeed already led to promising results. For
instance, the use of the thermophilic bacterium Ureibacillus
thermosphaericus (U. thermosphaericus) allowed cost savings
because, due to the possibility of a higher reaction temperature
(60−80 °C), sterile conditions were dispensable.251 A second
example is the use of Lactobacillus fermentum (L. fermentum)
possessing a high pH tolerance that allowed the AgNP
synthesis under basic conditions (pH 11.5) resulting in
enhanced silver recovery and reduction rates.253
With bacteria as biocatalysts, one diﬀerentiates between
intracellular254 and extracellular216 AgNP production. If
particles are generated and accumulated in various locations
inside the cell, it is deﬁned as intracellular synthesis.254 For the
extracellular NP production, either the cells ﬁrst take up silver
cations, reduce them in their interior, and then excrete the
particles to the outside of the cell,216 or only the cell-free
supernatant is used to produce AgNPs, which contains
secondary metabolites produced by the cells but no cells
themselves.163
In both cases, intra- or extracellular, the bioreduction of silver
can be carried out enzymatically and nonenzymatically. The
enzymatic reduction of Ag(I) to Ag(0) occurs for instance in
Gram-positive Bacillus licheniformis (B. licheniformis) via a
NADH-dependent nitrate reductase. This enzyme is located on
the membrane and is known to biosynthesize other nano-
particles as well such as gold or iron oxide.255 The enzyme
participation was investigated by the addition of several enzyme
inhibitors as, for instance, sodium azide, which reduced the NP
formation by 90%, while others showed merely a partial
inhibition.256 A partial inhibition of the AgNP formation was
also observed for strains of Gram-negative Enterobacteriaceae
treated with the natural monoterpene ketone piperitone (6-
isopropyl-3-methyl-1-cyclohex-2-enone).257 The participation
of enzymes has also been shown by Law et al.258 for the
extracellular silver reduction performed by Geobacter sulfurre-
ducens (G. sulfurreducens). Mutation experiments suggest a key
role of C-type cytochromes in the electron transfer chain
trough the periplasm and the outer membrane resulting in the
subsequent extracellular reduction of ionic silver. However, to
the best of the authors’ knowledge, no experiments concerning
the fate of the involved proteins of G. sulfurreducens have been
conducted to observe possible changes in the structure, shape,
or chemistry of the oxidized proteins. A second possible
mechanism for the extracellular reduction of metal ions
performed by G. sulfurreducens is the involvement of
cytochrome-free bacterial pili functioning as nanowires that
can be described as conductive protein appendage formed
through the polymerization of a single helical peptide subunit,
the so-called pilin. These pili are used to transport the electrons
that are necessary for the reduction of the metal.259 However,
the mechanism of the electron transport through these pili is
until now not well understood, but there is evidence that the α-
helical conformation of the pilin is of importance.260
For bacteria from the genus Morganella, both enzymatic and
nonenzymatic production of AgNPs has been discussed. While
Parikh et al.216 proposed the release of the silver binding
protein SilE (see previous section) to the outside of the cell
that then enables the formation of AgNPs by using the cell-free
supernatant, a recent study by Ramanathan et al.249 based on
electrochemical experiments suggested the involvement of a
silver reductase enzyme. After this intercellular reduction, the
formed AgNPs are subsequently released out of the cells.249
The fact that all Morganella strains being able to synthesize
AgNPs contained silE gene homologues underlines the
assumption that the AgNPs formation is associated with the
silver-resistance machinery.216,240,249 In addition, the study of
Ramanathan et al.249 showed for the ﬁrst time that the shape of
the formed AgNPs is a function of the temperature during the
growth of Morganella psychrotolerans (M. psychrotolerans) used
as biocatalyst, even though microorganisms predominantly tend
to produce spherical nanoparticles, which are the easiest to
create in terms of energy consumption and thus minimize the
eﬀort of the cells (Table 6).249
The advantages of a nonenzymatic bioreduction process are
that no special conditions to preserve the enzyme activity are
needed and that high concentrations of Ag(I) can be used.277
In general, the nonenzymatic reduction takes place via a two-
step mechanism in which the biosorption of silver cations is
followed by their bioreduction. The ﬁrst step occurs via the
binding of Ag(I) by biomolecules present on the surface of the
bacterial cell wall such as carbohydrates (via their hydroxyl
groups)253,284 or amino acids284 (via their side chains as
discussed in detail in section 2). The silver reduction step is
ascribed to the presence of reducing groups in the bacterial cell
wall. One example are polysaccharides present in the cell wall of
Gram-positive bacteria, which are able to carry out the
nonenzymatic reduction of silver, whereas Gram-negative
bacteria lacking those sugar polymers are not.253 In case of
Gram-positive lactic bacteria, the presence of exopolysacchar-
ides does not only provide additional silver binding sites, but
they also serve as electron donors leading to silver reduction.
Along with increasing pH, an augmented silver reduction rate
was observed, which can be explained by an enhanced
formation of the reactive aldehyde present in the open-chain
sugar.253 The proposed mechanism is shown in Figure 17.
A nonenzymatic silver reduction was also reported in the
biomass of Gram-negative Aeromonas or Gram-positive
Corynebacterium.277,285 In both cases, the accumulation of
Ag(I) and [Ag(NH3)2]
+ on the cell wall is proposed, which are
then subsequently reduced by aldehydes or ketones to metallic
silver. In addition to the above-mentioned nonenzymatic
factors contributing to the synthesis of AgNPs, it has also
been reported that hydroquinones behave as excellent electron
shuttles, which are released into the medium by Entero-
bacteriaceae, and may be responsible for the extracellular silver
reduction that was found by using the cell-free supernatants.257
With increasing interest in the green production of
nanoparticles, a growing number of organisms or their extracts
are tested for their silver-reducing properties. Besides
bacter ia ,272−275 , 280 a lso severa l fungi261−271 and
plants108,281−283 exhibit a potential for this green synthesis
(Table 6).
In summary, there are several possibilities for the formation
of AgNPs using bacterial cells, the intracellular or extracellular
synthesis that can both occur either enzymatically or non-
enzymatically. The complexity of the processes inside and
outside of the cells makes a deep understanding of the
mechanisms behind the AgNP formation rather diﬃcult. In the
majority of studies, the action of sil proteins is suspected to be a
crucial factor in the formation of AgNPs.249 Nevertheless, little
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progress in this area has been made because the mechanistic
studies in this area are limited predominantly to the detection
of silE homologues.216,240,249 Even though a deep under-
standing especially on the molecular level is still missing, there
are promising results showing that the tuning of AgNPs in size
and shape is possible with bacteria as biocatalysts. Nonetheless,
the authors of this Review are convinced that a detailed
understanding of the involved processes is a prerequisite for the
controlled and directed synthesis of AgNPs as well as for their
safe application as will be discussed for the medical ﬁeld in the
two following sections.
4. SILVER-BASED BIOMATERIALS IN THE MEDICAL
FIELD
Implant-related infections still remain an issue in medicine. For
example, 4.3% of orthopedic and 7.4% of cardiovascular
implants inserted in humans annually in the U.S. become
infected.286 Implant infections often result in pain for the
patients and malfunction of the implant, which may lead to the
replacement of the implant, or in extreme cases amputation or
death of the patient.287,288 Infections also considerably increase
medical costs. In the U.S. alone, costs of more than $ 3 billion
are generated every year due to such infections.286 Because the
number of patients receiving an implant is continuously
increasing and bacteria are becoming more and more resistant
to antibiotics,289 new strategies to prevent and cure implant-
related infections are currently under investigation and
development.290 For an implant to function properly, it should
be well integrated by the host cells. When bacteria are present,
they compete with the host cells for the adhesion on the
implant surface. When a bioﬁlm291 is formed on the implant
surface, that is, when there is an aggregation of bacteria
adhering to each other on the implant surface, the implant
cannot be well integrated by the host cells. This often leads to a
malfunction of the implant or to other health complications.
Moreover, it is normally impossible to eradicate this kind of
infections in vivo so that the only solution is the complete
removal of the implant.146 The ideal antimicrobial implant
would therefore prevent any bacterial adhesion without
aﬀecting host cell integration. Silver is a good candidate
because it has a high toxicity toward bacteria (see section 3),
but a lower toxicity toward eukaryotes (see section 5) oﬀering a
“therapeutic window” for the use of silver-based biomaterials.56
The EPA published a reference dose (RFD) for oral silver
exposure of 5 μg kg−1 d−1 with a critical dose estimated at
Table 6. Synthesis of AgNPs by Diﬀerent Microorganismsa
size [nm] shape organism strain ref
5−25 spherical F Aspergillus fumigatus 261
7−50 spherical F Aspergillus fumigatus 262
10−100 spherical F Cladosporium
cladosporioides
263
20−50 spherical F Fusarium oxysporum 264
2−5 spherical F MKY3 265
3−8 hexagonal
∼15 spherical F mushroom extract 266
5−25 spherical F Penicillium 267
Fellutanum
23−105 n.s. F Penicillium
brevicompactum WA
2315
268
50−200 pyramidal F Phaenerochaete
chrysosporium
269
∼71 spherical F Phoma sp. 3.2883 270
n.s. n.s. F Phytophora infestans 271
4−5 spherical G(+) B. cereus 272
40−50 n.s. G(+) B. licheniformis 273
∼50 n.s. G(+) B. licheniformis 255
10−80 n.s. G(+) B. licheniformis 256
5−15 seed-like G(+) Bacillus sp. 274
10−50 spherical G(+) Brevibacterium casei 275
10−15 n.s. G(+) Corynebacterium sp. SH09 276
11−20 spherical G(+) L. fermentum 253
n.s. n.s. G(+) Pediococcus pentosaceus
n.s. n.s. G(+) Enterococcus faecium
n.s. n.s. G(+) Lactococcus garvieae
15−500 n.s. G(+) Lactobacillus 254
20−30 spherical G(+) Streptomyces hygroscopicus 163
<20 n.s. G(−) Aeromonas sp. SH10 277,
278
∼50 spherical G(−) E. coli 252
5−20 spherical G(−) E. coli 164
5−35 spherical F Aspergillus niger
28−122 spherical G(−) Enterobacteriaceae 257
∼30 spherical G(−) G. sulfurreducens 258
2−5 (20 °C) spherical G(−) M. psychrotolerans 249
70−100
(4 °C)
nanoplates
100−150 triangular
100−150 hexagonal
15−25 spherical G(−) Morganella sp. 216
10−50 quasi-
spherical
G(−) Morganella spp. 240
<200 triangular G(−) P. stutzeri AG259 94,
279hexagonal
spherical
∼40 spherical G(−) Plectonema boryanum 280
1−200 octahedral
n.s. anhedral
10−100 spherical G(−) U. thermosphaericus 251
2−3 icosahedral P Alfaalfa sprouts 281
10−20 spherical P Azadirachta indica
(Neem)
282
55−80 quasi-
spherical
P Cinnamomum camphora 283
aF, fungi; G(+), Gram positive bacteria; G(−), Gram negative
bacteria; P, plants; n.s., not speciﬁed; sp., single species; spp., several
species.
Figure 17. Possible steps of the silver reduction by sugars present on
the cell surface in combination with free silver coordination sites (R).
Adapted with permission from ref 253. Copyright 2006 Springer
Science and Business Media.

ht
tp
://
do
c.
re
ro
.c
h
14 μg kg−1 d−1.12 Interestingly, Bunyan et al. showed that rats
supplemented with selenium or vitamin E tolerated a silver
exposure of as high as 140 μg kg−1 d−1. Thus, a 70 kg adult
should not exceed 350 μg per day.292
As it will be discussed in section 5, silver-containing
biomaterials are already present on the market,293 for example,
in wound dressings,88,294,295 contraceptive devices,296 endo-
tracheal tubes,297 and bone prostheses.293 They are also
intensively studied for preventing and treating infections on
burns,298 prostheses,299 catheters,300,301 vascular grafts,119
surgical instruments,128 and dental devices.47,90 One advantage
of using silver-containing materials to coat biomaterials, in
addition to silver’s good biocompatibility and good antimicro-
bial activity, is that they often protect both the inner and outer
surfaces and the proximity of a medical device in such a way
that the coating does not always need to cover the whole
implant surface to protect the implant from infection.31,38
The use of silver in medicine is highly debated, and there are
some contradictory studies as will be seen in the following.
Many factors inﬂuence the experimental observations during
antimicrobial activity and biocompatibility experiments. Among
others, the choice of the experiment type for the evaluation of
antimicrobial eﬃciency has a major importance on the
experimental conclusions, as it was pointed out by Klueh et
al.302 They observed that batch colonization experiments have
many disadvantages as compared to ﬂow cell experiments. In
batch assays, it is diﬃcult to deﬁne the hydrodynamic
conditions, to measure the correct cell deposition rate, to
determine the cell surface concentration, and to control the
reactor conditions, which are constantly changing. On the other
hand, ﬂow cell systems mimic much better the in vivo blood
vessel conditions. In their research on antimicrobial silver-
coated poly(ethylene terephthalate) (PET) fabric, it was
observed that both experimental procedures gave similar
antimicrobial activity results.302 However, while the batch
experiments suggested that their fabric was toxic to eukaryotic
cells due to the release of silver ions, the ﬂow cell tests did not
show any toxicity. Thus, appropriate tests need to be done as a
function of the applications. For instance, for hip implants, the
environment is more static than for vascular grafts so that for
the ﬁrst case a batch colonization experiment would be more
appropriate while for the second material a ﬂow cell
measurement would be chosen.
In the following subsections, three diﬀerent strategies for
making silver-based biomaterials will be discussed, as well as the
diﬀerent deposition methods and the eﬀect of incorporating
silver ions or nanoparticles on the mechanical properties of
certain materials.
4.1. Types of Silver-Containing Biomaterials
Silver-containing biomaterials could be classiﬁed in many
diﬀerent ways. In this Review, we chose to divide them into ﬁve
categories: (i) metallic silver coatings, (ii) silver-containing
nanocomposites, (iii) silver-containing polymers, (iv) surface
modiﬁcation with ionic silver compounds, and (v) hybrid silver
materials. The advantages and examples of each type of material
are described below.
4.1.1. Metallic Silver Coatings and Silver’s Antimicro-
bial Eﬃciency. Recent studies employing metallic silver as an
implant coating on catheters and orthopedic pins resulted in
good antimicrobial activity in vitro,303−305 but failed in vivo to
prevent bacterial invasion in a signiﬁcant way.306,307 Moreover,
despite their low antimicrobial activity found in some in vivo
studies, implants coated with metallic silver signiﬁcantly
increased the silver serum level in such a way that, according
to Masse et al.,306 they cannot be ethically used in medicine.
One reason for the poor performance of metallic silver coatings
during in vivo tests is that silver interacts with the proteins in
the blood plasma, which rapidly bind and inactivate the released
silver ions, and therefore silver loses its antimicrobial activity
(see section 3.1).308 Another possible reason for the poor
action of metallic silver coatings is that some metallic silver
coatings do not actively release silver ions.290,309 In fact, it was
shown that the rate-determining step for silver release from
metallic silver materials depends on the mechanism by which
Ag(0) is oxidized into silver ions as it was already mentioned in
section 3.1.1.310 Consequently, the rate depends on the ﬁlm
thickness and surface morphology,311 and thus on the
deposition method (see section 4.2). In a later in vivo study
performed by Gosheger and co-workers,312 titanium mega-
endoprostheses coated with metallic silver showed a signiﬁcant
decrease in the infection rate as compared to uncoated
prostheses in rabbits. Even though they observed high
concentrations of silver ions in animals that received coated
implants, they did not observe any pathologic or histological
changes. This is understandable because elemental analyses do
not diﬀerentiate between free silver ions and those inactivated
by the binding to proteins. Their clinical study on humans
showed similar results for titanium−vanadium megaprostheses
coated with elemental silver deposited by galvanic deposition
method.313 In none of the 20 patients, any sign of argyrosis, the
eye condition of argyria caused by improper exposure to silver,
was observed as the silver ion concentration in the blood did
not exceed 56.4 ppb (56.4 μg L−1). In addition, the ﬁbrous
tissues surrounding the implant showed a normal ingrowth on
the implant without any evidence of toxicity to silver, even
though the silver ion concentration within those tissues
exceeded 1500 ppb (1500 μg kg−1). Nonetheless, and because
the use of silver coatings on medical devices is highly
controversial and debated,314 some studies suggest that
materials containing silver ions or AgNPs would have a better
antimicrobial activity than metallic silver coatings.315
Silver Nanoparticles. AgNPs as well as compounds
containing stabilized silver ions have a good silver ion release
ability,158,316 which makes them more attractive for the
development of antimicrobial biomaterials. The size and
monodispersity of nanoparticles are apparently not always
essential for good activity. In fact, polydispersity can even be
beneﬁcial for increasing the duration of the antimicrobial
activity based on diﬀerent release kinetics.317 However, in most
cases the size of the silver particles was shown to be very
important (see section 3.1). This is also demonstrated in an in
vitro study318 in which a commercially available silver-coated
silicone catheter could not completely eradicate any of the
strains S. aureus, E. coli, or Propionibacterium acnes. Even though
the silver-coated catheter showed some activity at low inocula
of 104 colony-forming units per milliliter (cfu mL−1) and
partially killed the bacteria at high inocula of 107 cfu mL−1, the
bacterial colonization was regenerated after 3 or 4 days. Two
possible reasons for this poor performance are that the catheter
surprisingly contained only a little amount of silver as compared
to the speciﬁcations, and that the silver particles were too big
(about 500 nm in diameter) for eﬃcient silver ion release.318 It
is also likely that some silver particles were buried too deep
inside the silicone material so that they were inaccessible. In
addition, AgNPs that are not stabilized tend to aggregate and
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lose their antimicrobial activity and sometimes their bio-
compatibility. It is therefore essential to protect AgNPs, for
example, in a polymeric network.319,320 A method to hinder
AgNP aggregation can be simply coating the particles with
poly(vinyl sulfonate) (PVS). PVS renders them more
negatively charged so that they can more easily interact with
positively charged surfaces, such as amine-functionalized
substrates, and therefore have a better adhesion while staying
separated from each other thanks to stronger electrostatic
repulsion.315,317 The importance of surface charge of AgNPs
was already brieﬂy described in section 3.1.
The eﬃciency of silver-based antimicrobial materials is also
highly dependent on their surface morphology and en-
ergy.321,322 In fact, rougher and more hydrophilic surfaces
facilitate the bacterial adhesion in such a way that bacteria are
more resistant to antimicrobial agents including silver. In
addition, as the total surface energy increases, the bacterial
adhesion also increases. The surface roughness and surface
energy can be modiﬁed simply by using a diﬀerent reducing
agent for the formation of AgNPs from a silver ion
solution.321,322 In some cases, the addition of silver particles
to a material can increase its hydrophobicity and at the same
time decrease the adhesion of bacteria to its surface.323 Many
other factors inﬂuence the antimicrobial eﬃciency of silver. For
example, it is highly dependent on its oxidation state, Ag(I)
being a stronger biocide than Ag(II) or Ag(III), which are
oxidation states also known for silver even though less common
than Ag(I).324 The method of preparation of the silver-
containing materials has therefore an important impact on its
behavior.
4.1.2. Silver-Containing Nanocomposites. Another
strategy for producing an antimicrobial implant is based on
silver-containing polymers and composites. Titanium-based
implants (e.g., TiAlNb, Ti, TiAlV) are commonly used as
biomaterials for load-bearing implants due to their well-known
biocompatibility, mechanical strength, and corrosion resist-
ance.325−327 However, these materials normally have a low
antimicrobial activity on their own, if any. To render such an
implant antimicrobial, a coating is normally required. Santillan
and co-workers89 have successfully grown 4 nm AgNPs on
23 nm titania nanoparticles. This TiO2-Ag nanocomposite
enables a homogeneous distribution of silver on a substrate and
therefore allows a controlled silver release. Coated on a
titanium substrate, this TiO2-Ag nanocomposite was shown to
be bioactive, suggesting that it would allow good cell
integration. Moreover, this nanocomposite did not signiﬁcantly
aﬀect the mechanical properties as compared to uncoated
titanium,89 which suggests that it is an interesting coating for
medical implants. The combination of the antimicrobial
activities of silver and titanium oxide has also been previously
reported to prevent infectious contamination by inserting such
nanoparticles in facial masks without provoking any evidence of
inﬂammation for the users.103 On another hand, Huang et al.328
propose a silver-containing tantalum nitride (TaN-Ag) material
as a coating for titanium-based implants. TaN-Ag coatings
considerably decrease the bacterial adhesion of S. aureus as
compared to uncoated titanium and silver-free TaN. TaN-Ag
coating has also shown excellent biocompatibility as it allowed
the cell attachment of human gingival ﬁbroblasts in an even
more eﬃcient way than uncoated titanium.328 Another material,
the silver-doped porous P2O5-SiO2 monoliths that were
prepared by a sol−gel method, had a stable silver release in
water at 30 °C over a period of 28 days, thus demonstrating
that silver-containing nanocomposites can provide a slow
release of silver ions.329 This 4-week period would oﬀer a good
short-term protection for the critical period330 after the surgery.
However, even though the expected time for an orthopedic
implant to stay in the human body is between 10 and 15
years,331 in the literature, no long-term studies are described for
silver-based implant materials according to our knowledge.
4.1.3. Silver-Containing Polymers. An alternative
method to enhance the properties of silver-based materials is
the incorporation of silver ions or nanoparticles into hydrogels.
Many groups have successfully developed such hydrogels that
allow a slow and controlled release of silver ions,309 as, for
instance, a PET surface modiﬁed by silver ion implantation,332
silver nitrate-catalyzed polyacrylamide gels,333 and PET-based
hollow ﬁbers containing silver particles.334 Slow and controlled
silver release could also be achieved from polymers. As an
example, Damm et al.335 could fabricate a material that
maintains a constant antimicrobial eﬃciency over long periods
of time. In fact, they synthesized a polyamide 6-silver
nanocomposite that, even after 100 days immersed in water,
still releases silver at the same rate demonstrating a zero-order
release.315 The silver release of some silver-containing materials
is given in Table 7.
It is often easy to trap silver ions or AgNPs within a polymer
matrix. For many resins, it can be performed by immersing the
polymer in a silver-containing solution and then adding a
reducing agent to form AgNPs. The porosity allows the
diﬀusion of silver ions within the interior of the polymer matrix
in such a way that silver ions can interact with the functional
groups of the polymer, as depicted in Figure 18.340 The
reductant then also diﬀuses through the matrix and induces the
formation of well-dispersed AgNPs on the surface as well as in
the interior of the resin.340 This kind of impregnation with
silver has shown advantages as compared to simple coating,
such as a slower silver release for nanoparticles that are located
deeper inside the matrix and the protection of the whole
biomaterial, not only of one surface.7
Travan and co-workers341 obtained a noncytotoxic hydrogel
that successfully killed Gram-positive bacteria including S.
epidermidis and S. aureus, which are major concerns for
catheters and prosthetic implant infections, respectively, and
Gram-negative bacteria, such as E. coli. They used a lactose-
substituted chitosan, the so-called Chitlac, to embed AgNPs in
Table 7. Examples of Time Needed To Reach the Maximum
Silver Concentration (Plateau) for Diﬀerent Materialsa
material type medium
temp
(°C)
time to reach
plateau ref
Ag-doped P2O5−SiO2 monoliths water 30 more than
28 d
329
polyamine 6/Ag nanocomposite water rt more than
100 d
335
Ag-doped perﬂuoropolyether-
urethane
PBS 37 1 d 336
Ag-doped perﬂuoropolyether-
urethane siloxane ﬁlm
PBS 37 4 d 337
Ag-containing PET hollow ﬁbers PBS 37 2 d 334
PVC silver zeolite sterile
urine
37 5 d 338
AgNP in acrylic resin water rt 2 d 339
aPBS stands for phosphate buﬀered saline, which is a commonly used
buﬀer solution (rt, room temperature; d, day).
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a very disperse manner, preventing their aggregation over long
time periods (more than 90 days). Their silver-containing
hydrogel allows the AgNPs to contact the cellular membranes
without being taken up by the cells. It therefore showed speciﬁc
toxicity toward bacteria, but not toward eukaryotes because
eukaryotic cell membranes are considerably less sensitive to
silver. In addition, this Chitlac hydrogel only very slowly
releases silver ions in saline solutions, so that it is considered to
be noncytotoxic for humans.341 In a later work, Travan and co-
workers342 demonstrated the eﬃciency of this hydrogel as an
antimicrobial coating for methacrylic thermosets, suggesting its
possible application to dental and orthopedic implants.
In silver-containing hydrogels, the silver release rate depends
mostly on the rate of water diﬀusion in the polymer matrix.309
This can be controlled by the crystallinity of the polymer
matrix,343 the ﬁller type,344 the silver particle morphology,345
the silver concentration, the silver grain speciﬁc surface area,
the physical state of the composite, and the physical changes
due to the incorporation of silver.309 These factors can be
varied to increase the antimicrobial activity while decreasing the
toxicity of silver. A slow release of silver ions in such systems
can also be controlled by the adhesion of the silver ions or
nanoparticles. In other words, strongly attached silver to the
polymer will be released slower than weakly attached silver.309
In an in vivo study, Boswald and co-workers346 demonstrated
a good biocompatibility for a silver-impregnated catheter. They
placed normal and silver-containing poly(urethane) (PU) and
silicone tubes in rats and observed the incidence of abscesses
due to this intervention. For PU tubes, there was no signiﬁcant
diﬀerence between the silver-impregnated and the silver-free
tubes. On the other hand, silver-impregnated silicon catheters
showed a considerable decrease in the abscess incidence as
compared to the normal silicon tubes. Histological tests of the
specimens receiving a silver-containing catheter did not show
the presence of silver particles in any of the subcutaneous,
muscular, or peritoneal tissues.346 Clinical studies using an
urinary catheter coated with a hydrogel embedding silver ions
also showed very promising results for the use of such medical
devices. In fact, a reduction of infection cases was observed as
compared to uncoated catheters,303,347 which also results in a
signiﬁcant reduction in medical costs.303 Plowman and co-
workers348 developed a model for evaluating the potential
beneﬁts of the routine use of silver-coated urinary catheters.
They compared the additional medical costs due to infection
occurrence to the costs of production of silver-coated catheters,
considering also their eﬃciency of about 32%,347 and they
concluded that their routine use would signiﬁcantly reduce
medical costs.348
Because textiles are recognized as an ideal medium for
microbial development, AgNPs are proposed as a component
in fabrics such as polyester or cotton fabrics. Some works
demonstrate that embedding silver within a textile, similarly to
polymers, can stabilize the AgNPs in such a way that they can
retain their biocidal activity for a longer time and thus prevent
microbial development.349,350 This is of great interest for the
fabrication of antimicrobial bandages, as an example.
Biodegradable Coatings. The use of biodegradable coatings
containing silver ions might also be beneﬁcial for a controllable
silver release. For example, it is possible to dope phosphate-
based glasses with silver to prevent urinary tract and wound
dressing infections. The release of silver ions was shown to be
dependent on the degradation of the glass.324,351 Good
biocompatibility as well as antimicrobial activity have also
been demonstrated for bone cements loaded with AgNPs,352,353
such as HA cements, which are commonly used in implants to
promote bone ingrowth for bone regeneration,353 and gelatin
nanoﬁbers or ﬁlms loaded with AgNPs.354,355 Moreover,
ﬂexible and biodegradable silver-containing nanocomposites
oﬀering prolonged antibacterial protection were developed as
good materials for dental or reconstructive bone surgery.356
Liposomes were also used to trap silver within a polymer
coating. In fact, Malcher and co-workers357 could make an
antimicrobial composite containing liposomes ﬁlled with silver
nitrate using a sonication technique. They ﬁrst ﬁlled the
liposomes with silver nitrate solution, and then, with the help of
poly(L-lysine) (PLL), they forced these liposomes to aggregate.
Figure 18. Proposed model for the formation of silver particles around and/or within the bead macrostructure of two diﬀerent resins: (a) GT73 and
(b) IRC748. Adapted with permission from ref 340. Copyright 2007 John Wiley and Sons.
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These aggregates were then incorporated into a multilayer PLL-
polyanion ﬁlm. This coating was shown to be very eﬃcient
against E. coli invasion.
Qureshi et al.358 have also developed a bioabsorbable coating
for implants. This coating, made of poly(L-lactic acid) (PLLA),
contains about 7 × 105 ppb (7 × 105 μg kg−1) cellulose-
stabilized AgNPs. It demonstrated very good in vitro
antimicrobial activities against both Gram-negative and Gram-
positive bacterial strains. During the ﬁrst day, the silver release
reached 177.4 ppb (177.4 μg L−1), which did not aﬀect the in
vitro viability of human HeLa cells.359 On a longer time scale,
this biomaterial releases silver ions at a slower rate.
In short, the embedment of silver ions or AgNPs within a
polymer stabilizes the silver compounds and allows a slower
release and therefore a longer antimicrobial eﬃciency.
4.1.4. Surface Modiﬁcation with Ionic Silver Com-
pounds. Balazs et al.360 clearly demonstrated that a simple
surface modiﬁcation can signiﬁcantly prevent and eliminate
bacterial adhesion on medical devices. In fact, the chemical
modiﬁcation of poly(vinyl chloride) (PVC), which is
commonly used in endotracheal tubes, with sodium hydroxide
and silver nitrate prevented any bacterial invasion for more than
72 h.360,361 A second promising result was provided by Berra et
al.362 who observed in a clinical study that PU tubes that are
internally coated with silver sulfadiazine prevented the
occurrence of bacterial colonization without any observable
negative eﬀects.362
Another strategy for surface modiﬁcation with silver involves
the use of coordination polymer networks and polymorphs to
capture and slowly release silver ions. (Iso)nicotinic acid
derivatives (of type 21) have been intensively studied in our
group for this purpose,363−369 thanks to their ﬂexible backbone
and their good biocompatibility.370,371 This type of coating was
shown to eﬃciently prevent implant infection on dental
devices.372 Their tunable solubility, stability, and antimicrobial
eﬃciency make coordination polymer networks interesting
“smart” coatings for biomaterials. They can be used to modify
gold and titanium surfaces with, for example, [Ag(ethane-1,2-
diyl diisonicotinate)NO3]n (22), as depicted in Figure 19, using
disulﬁde 23 as anchor molecule. This coating shows a very
good antimicrobial activity against a broad spectrum of
pathogens while having a low toxicity. In vivo studies show
that this coating was eﬃcient against the implant infection
strains S. epidermidis and S. aureus over 21 days, independently
of whether they carried the bioﬁlm-forming ica-gene or not. We
also observed that, even though there is formation of a bioﬁlm,
the antimicrobial action of silver was not aﬀected. This property
seems to be related to a mechanism involving the binding of
silver to the amino acids containing thiol groups, including the
respiratory chain and citric acid cycle enzymes, leading to their
inactivation. Another eﬀect of silver in bacteria is the formation
of hydroxyl radicals, leading to DNA damages,207 as discussed
in section 3.1.
A similar strategy has been developed by Amalric and co-
workers.373 They propose a nanosized silver-containing
mercaptododecylphosphonic acid coating obtained by a simple
chemical surface modiﬁcation. Despite its low silver concen-
tration, this self-assembled monolayer coating was shown to
reduce bacterial adhesion and bioﬁlm formation by more than
99.9% on both titanium and stainless steel samples.373
In short, the surface modiﬁcation of implants with silver
compounds oﬀers an interesting strategy to prevent infections.
4.1.5. Hybrid Silver Materials − Synergistic Eﬀects.
Many researchers propose the combination of silver with
another antimicrobial agent to enhance its biocidal eﬃciency.
Thanks to this synergy eﬀect, these so-called hybrid materials
either provide diﬀerent ways to kill bacteria, or one component
can simply enhance the eﬀect of the other.
An example of hybrid antimicrobial systems is the dual action
of a hydrophobic material with the release of silver ions, which
have recently been suggested as suitable antimicrobial coatings
for medical devices.336 This was also demonstrated with silver-
doped perﬂuoropolyether-urethane siloxane thin ﬁlms depos-
ited on a glass substrate.337 The hydrophobic sites of this
coating are proposed to protect the action of silver ions. In fact,
the hydrophobic sites seem to inhibit the attachment of ionic
species that might reduce the available silver ions located on the
surface or form silver salt deposits (see Figure 25, section 5.5),
which would considerably reduce the biocidal action of silver, as
shown in section 3.1. As perﬂuoropolyether-urethane siloxane
protects silver from deactivation, the released silver ions
protected these hydrophobic sites against S. epidermidis
attachment and colonization,337 even though this strain was
shown to colonize preferentially hydrophobic sites over
hydrophilic sites.374 The silver-doped perﬂuoropolyether-
urethane siloxane thin ﬁlms showed very good antimicrobial
activity against both S. epidermidis and A. baumannii bioﬁlm
formation.337 In addition, the introduction of ﬂuorocarbon and
AgNPs increases the biostability of these polyether urethane
derivatives,375,376 which makes them more attractive for
medical uses.
A second example for hybrid silver materials was mentioned
earlier in section 2.3.1. Eby et al.140 proposed the combination
of silver with lysozyme, an antimicrobial enzyme for making an
antibacterial and self-cleaning coating for surgical instruments.
They also realized that the use of lysozyme can be beneﬁcial for
Figure 19. Synthesis and surface treatment with the silver
coordination compound [Ag(21)NO3]n (22). (a) Formation of the
silver coordination compound 22 and (b) its deposition on Au(III)
plates using the disulﬁde 23 as anchor molecule for the surface
modiﬁcation. Possible modes of AgNPs internalization. Adapted with
permission from ref 207. Copyright 2010 American Society for
Microbiology.
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the design of silver-containing coatings. In fact, lysozyme can be
used as a reductant and stabilizer during the synthesis of AgNPs
in methanol. The nanoparticle synthesis did not aﬀect the
electrochemical properties of the enzyme, which are necessary
for the electrophoretic deposition to be performed without the
addition of other electrolytes. Eby et al.140 also observed that
the presence of lysozymes increases the adsorption strength of
AgNPs onto stainless steel surfaces. In addition to the biocidal
activity of lysozyme, this coating would also allow a release of
silver ions. Even though the antimicrobial eﬃciency still
requires improvement for such coating, this lysozyme−silver
hybrid coating is very promising for the development of
antimicrobial robust and self-cleaning medical instruments.140
Because chitosan has also been shown to have antimicrobial
activity against a broad spectrum of bacterial strains,377 it is not
surprising to ﬁnd many studies combining both silver and
chitosan. For example, Fu et al.378 proposed a coating
consisting not only of silver and chitosan, but also of heparin
as an anticoagulant. The nanosilver was deposited on PET,
which is a material commonly used for cardiovascular medical
devices. This coating was fabricated by successive layers of
chitosan−silver nitrate complex and heparin, and the nano-
particles were synthesized by the reduction of silver ions by
ascorbic acid. They proposed this material to eradicate two
major problems encountered in cardiology: cardiovascular
infections, as it is one of the most commonly occurring
postimplantation infections, and thrombogenicity, that is, the
formation of a clot due to the contact of a material with blood.
Indeed, the strong anticoagulating properties of chitosan and
heparin379 were not aﬀected by the presence of silver. This
coating is therefore not only easy and cheap to synthesize, but it
has also good antimicrobial, anticoagulating, and biocompatible
properties.378
Other studies have demonstrated the strong antimicrobial
activity of the silver−chitosan combination against both Gram-
negative and Gram-positive bacteria, including the MRSA.380
This combination was shown to also have a good
biocompatibility in vitro and in vivo so that its use has been
proposed for medicine,381 for example, in burn and wound
dressings,382−385 and in food packaging.315,381,386 Huang et
al.380 oﬀer an explanation for the high eﬃciency of silver−
chitosan material. They suggest that their combined actions are
synergistic rather than being simply additive. Chitosan renders
the bacterial cell membrane more permeable in such a way that
silver ions can penetrate more easily the bacteria and kill them.
This theory is conﬁrmed by their observation that Gram-
negative bacteria, having a high intrinsic permeability barrier,
that is, being very impermeable to exchanges with the
environment, are more aﬀected by this synergy action of silver
and chitosan than Gram-positive bacteria. They also observed
in vivo that a chitosan−silver bandage oﬀers a very good
treatment against bacterial infection in burns.380 The exact
molecular mechanism of action and the structure of this hybrid
material still remain unclear.
Cao and co-workers387 suggested that the good antimicrobial
activity against S. aureus and E. coli and the low toxicity to
eukaryotes, which they observed for their titanium matrix
containing AgNPs, is due to a combined action of silver and
titanium. They explained this diﬀerence in biological activity
against prokaryotic and eukaryotic cells by a microgalvanic
eﬀect created by silver and titanium, which is aﬀecting the
proton active transport of the bacterial plasma membrane,
making the material more toxic to bacteria.
In short, silver-containing compounds can beneﬁt from the
combinations with other materials to increase their antibacterial
eﬃciency and/or their stability.
4.2. Deposition Processes
For many of the antimicrobial coatings shown so far, one
characteristic that is often forgotten for an antimicrobial coating
to be commercially applicable is their ability to be easily and
economically deposited on an implant. The choice of the
coating method is of major importance as it must ensure a good
adhesion of the coating components on the substrate and
maintain the proper chemical compositions, structure, and
bioactive properties.388 Thus, there is no “the one and only”
technique that can be used for all materials and applications.
Examples of coating techniques are ion implantation,332 slip-
casting, glue-bonding, isostatic pressing, rolling, electrochemical
deposition, casting, and plasma sputtering.389−392 Some of the
most commonly used techniques require heating of the coating
to high temperature. However, as demonstrated by Taylor et
al.,393,394 nanocrystalline silver is unstable at elevated temper-
atures, resulting in considerable changes in its physical and
chemical structure, which is considered to play a major role in
its antimicrobial activity.393 In fact, the silver release in
polymer-based dressings treated at temperatures above 75 °C
was considerably reduced in such a way that its antimicrobial
activity is considerably aﬀected.394 Thermal deposition
processes are therefore not desirable for many silver-containing
coatings. Nonetheless, Ando and co-workers395 have demon-
strated that a silver-containing calcium phosphate layer could
be thermally sprayed on titanium substrates. This coating also
shows interesting antimicrobial activity, as well as a good
biocompatibility. A silver-doped diamond-like carbon coating
could also be generated and deposited using a pulsed ﬁltered
cathodic vacuum arc. This surface showed excellent hemo-
compatible and antimicrobial eﬃciency so that it was
recommended for implants and medical devices.396
Many other deposition techniques have been proposed and
tested for medical devices with coatings that are heat-sensitive.
Galvanic deposition was used to coat metal-based prostheses
with elemental silver. The in vivo tests showed that this coating
remained intact after a long period of about 19 months.313 The
deposition of a metallic material on a polymer is more
complicated than on another metal because metals and
polymers have diﬀerent surface energies, leading to a weaker
adhesion on polymers. Thus, an electroless plating process has
been proposed as a cheap and easy method to deposit silver on
poly(ether urethane) (PEPU) without the use of vacuum.397,398
Nonetheless, plasma treatment is still recommended because it
greatly improves the silver adhesion on the polymer. Better
adhesion results in the formation of a higher amount of small
silver clusters instead of only few big clusters with weak
adhesion.398 As smaller nanoparticles exhibit a higher
dissolution rate, the antimicrobial eﬃciency of this (PEPU)−
silver composite increases.397 On the other hand, plasma
treatment results in some chemical changes to the polymer
surface such as and an increase in carbonyl, alcohol and alkene
groups.399 The presence of additional CO groups probably
explains the better adherence of silver to plasma-treated
polymer surfaces.398
It is important to keep in mind that the morphology, and
therefore the silver release eﬃciency, of metallic silver coatings
can be very dependent on the deposition technique used and its
parameters. To coat the inside of silica capillaries with silver,
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Wen et al.400 used the wet chemistry deposition method. They
realized that as the volume of silver nitrate as precursor for the
silver coating increases, the grain size and the surface roughness
of the coating also increase.400 When the silver ﬁlm was
fabricated by ﬁrst producing AgNPs by laser ablation of
microparticle aerosols and then depositing them by supersonic
jet deposition, the morphology and density can be controlled.
Increasing the annealing temperature produces bigger grains,401
and rapid heating produces ﬁlms of higher density.402
A well-adhered silver layer was successfully deposited on PU
and polyethylene substrates during a magnetron deposition
process combined with a neutral atom beam plasma source at
70 °C.403 The resulting substrates have good antimicrobial
activities and low cytotoxicity. However, even though it is
successful for soft polymer substrates, this combined deposition
technique is not as eﬃcient for hard polymer substrates. In fact,
coatings on silicon for example exhibit less adhesion and
become more cytotoxic as compared to the soft polymers.403
Co-sputtering of silver together with the embedding mineral,
such as HA, was also shown to be eﬀective to create a
nanocomposite coating with well-dispersed silver.353
Figure 20 lists the surface modiﬁcation techniques most
published for coating biomaterials. As it can be observed, the
layer thickness is highly dependent on the chosen deposition
technique. As pointed out by Dong et al.404 for a long lasting
antimicrobial coating, it is often preferable to have a thick
coating as it might be subjected to dissolution and wear forces.
They also demonstrated that the silvering of a stainless steel
surface could be eﬀectively achieved by a double glow plasma
alloying technology, resulting in a good antibacterial material.
This silvering resulted in a harder stainless steel material, which
in turn improved the wear resistance. This material can
therefore be beneﬁcial for load-bearing implants as they are
highly exposed to surface damage, to improve the bioactivity
duration and reduce the contamination by the implant residues.
Reactive pulsed laser deposition (PLD) could also be used to
fabricate nanostructured Ag4O4 (Ag(I)−Ag(III) oxide) ﬁlms
with good antimicrobial activity and allows to control the
crystallinity, the grain size, and the morphology of these
ﬁlms.405 Ag4O4 consists of two monovalent and two trivalent
silver ions per molecular crystal, forming a distorted face-
centered cubic arrangement of silver ions.406 Ag4O4 has already
been suggested for water treatment as it was shown to kill E.
coli and Streptococcus faecalis.407
Other methods for making silver-containing coatings, such as
the sol−gel method for colorless silver-containing silica glass
powders for dental implants408 or multilayered silver-containing
TiO2 ﬁlms,
409 are eﬀective to embed silver ions and gradually
release them.
As it was just presented, the choice of the deposition
technique is of major importance for obtaining eﬃcient
antimicrobial coatings for implants.
4.3. Mechanical Properties
One major concern about inserting silver compounds or
nanoparticles within biomaterials and coatings is that it might
aﬀect its mechanical properties. In some cases, the silver
component can be beneﬁcial for the overall material. For
example, in addition to its good antimicrobial activities, the
dental acrylic resin embedding AgNPs developed by Kassaee et
al.339 shows slightly improved ﬂexural strength and modulus as
compared to the commonly used dental acrylic resin.339 The
use of AgNPs in dental acrylic resins is therefore favorable as
compared to the incorporation of other silver-containing
compounds such as Ag-Z. In fact, even though Ag-Z has
shown good antimicrobial activity against bacteria, as shown in
section 3.1.3, and a well-controlled silver release,338,339,410 the
incorporation of more than 2.5 wt % Ag-Z in the acrylic resin
resulted in signiﬁcant deterioration of its mechanical proper-
ties.411 On the other hand, the introduction of Ag-Z in PVC
composites, even at a concentration up to 20 wt %, did not
result in any signiﬁcant changes in tensile strength, elongation
at break, viscosity, or thermal properties. Only the modulus is
increased with the increased concentration of zeolite in PVC,
making the composite stiﬀer, but not enough to inﬂuence its
processability and formability. Moreover, its antimicrobial eﬀect
could be activated with diluted acid,338 which is of interest
because bacteria tend to acidify the medium around them.
Good mechanical properties were also observed for Ti-based
alloys containing silver.412−415 For example, the addition of
silver and copper improves the mechanical strength of titanium
alloys without aﬀecting the corrosion resistance, making this
Ti−Ag−Cu alloy very attractive for dental applications.416
Another example of improved mechanical properties is that the
swelling properties of some hydrogels could also be altered by
incorporating silver ions. This is the case for a silver-containing
thermoplastic nanoﬁbrous hydrogel that shrinks during water
uptake, while normally hydrogels swell. This unusual hydrogel
can therefore have interesting applications for wound
dressings.417
Despite these promising examples, silver integration does not
always lead to better mechanical properties. Thus, Radheshku-
mar and Münstedt noticed a signiﬁcant decrease in toughness
and elongation strength when 2 wt % silver powder (2 × 107 μg
kg−1) having a speciﬁc surface area of 0.78 m2 g−1 is introduced
into polyamide, even though the silver powder was well
dispersed. As the silver concentration increases, the mechanical
properties deteriorate.418
In short, we have observed that the addition of silver, in
either metallic bulk, ionic, or nanoparticular form, is generally
beneﬁcial for improving the antimicrobial properties of
biomaterials and that the antimicrobial activity of silver can
be ampliﬁed by the synergistic eﬀects of several agents.
Figure 20. Eﬀective thicknesses of the four most published surface
modiﬁcation techniques in addition to double-glow plasma alloying for
achieving antibacterial surfaces. The bars indicate the maximum and
minimum thicknesses as published. Possible modes of AgNPs
internalization. Adapted with permission from ref 404. Copyright
2011 Elsevier.
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However, the properties of an implant material, such as its
mechanical properties, can be altered by the addition of silver in
any form, and the deposition technique, in the case of
antimicrobial coatings, can also inﬂuence its eﬃciency. Finally,
when treating an implant with silver, it is wise to avoid the
generalization of eﬀects and the transfer of properties from one
system to the other, but rather test and conﬁrm all derived
properties with regard to the applications, in vitro and in vivo,
as the properties of silver-containing materials can signiﬁcantly
vary depending on the environment.
5. BIOCOMPATIBILITY OF SILVER
Medical devices need to possess, next to being antimicrobial, a
second important property: they must be biocompatible.
Indeed, biocompatibility has become the central request for
medical applications of materials and devices before being
placed in the body. The determination of cytotoxicity implies
that a material has to be (i) free of damaging eﬀects on the
host, (ii) able to elicit a beneﬁcial host-response for optimal
function, and (iii) safe, which deals with the exclusion of
deleterious eﬀects of a biomaterial on the organism itself.
As discussed in section 4, manufacturers are increasingly
looking at silver as a promising solution to prevent infections in
the medical ﬁeld.419 Free silver ions, because of their low
cytotoxicity to mammalian cells420−423 and broad-spectrum
antimicrobial activity, have gained attention in a wide range of
applications in the healthcare sector with a high degree of
commercialization. Silver coatings of foreign materials have
been safely used in medicine for many years and are proven to
reduce infection rates of medical devices in vitro and in
vivo.346,347,420,424−430 They are used in burn wound dressings,
orthopedic and dental implants, bone prostheses, surgical
instruments, intravascular catheters, prosthetic heart valves,
cardiac pacemaker, and contraceptive devices.431,432 These
devices interact with the human body at diﬀerent levels and
places, and we classiﬁed them according to their contact levels
with the human body as discussed in the following subsections.
5.1. General Routes of Silver Exposure
The human body has several semiopen interfaces such as the
respiratory tract, the gastrointestinal tract, and the skin (Figure
21), which can get exposed to three major product categories:
food, consumer products, and medical products.
Inhalation of vapors, gases, mists, or particulates is one of the
major routes of entry of silver compounds into the body. Once
inhaled, silver compounds, and more speciﬁcally AgNPs, are
either inhaled or deposited in the respiratory tract, causing
damage through direct contact with tissues, or are diﬀused into
the blood through the lung−blood interface. The respiratory
tract is, apart from the skin, the only organ system in direct
contact with the environment. Nasopharyngeal (ciliated
epithelium and mucous glands), tracheobronchial (consisting
of trachea, bronchi, and bronchiols) and pulmonary acini (small
bronchioles with alveoli connecting to pulmonary capillaries)
are components of the respiratory tract.433 The distribution and
disposition of silver particles in the respiratory tract depend on
various factors including particle size and breathing force.434
Indeed, particles with a size of 5−30 μm are deposited in the
nasopharyngeal region, whereas 1−5 μm particles are deposited
in the tracheobronchial region. For AgNPs with a size of less
than 1 μm, deposition occurs in the alveolar region by diﬀusion
and Brownian motion resulting in a deep penetration of AgNPs
into the lungs, followed by the absorption into the blood
system and distribution into the organs.435
Ingestion of silver compounds is the second most common
route of exposure. Indeed, silver may enter the body through
the mouth, throat, or digestive tract after ingesting silver-
containing food, water, or medication. The body of an adult
normally contains ca. 29 μg kg−1 of silver. Our daily oral intake
of silver is 20−80 μg d−1 of which approximately 10−20% are
absorbed436 by the gastrointestinal tract, mainly by the
duodenum and small intestine. Insoluble silver compounds in
the ﬂuids of the gastrointestinal tract (stomach, small, and large
intestines) are generally excreted, whereas other silver
compounds that are soluble are absorbed through the lining
of the gastrointestinal tract. They are then transported by the
blood to internal organs (see section 5.3).437
Dermal exposure represents the third important absorption
route for silver.203 The skin is, in terms of weight, the largest
organ of the body. It provides a barrier between the
environment and other organs (except the lung and eyes)
and is a defense against many chemicals. Silver can enter the
body through the skin when it is in direct contact with solutions
containing silver compounds, such as those used in
photography, or when in contact with silver wound dressings
as will be discussed in the following section in the context of
exposure to silver medical products.
5.2. Exposure to Silver-Containing Medical Products
As discussed in section 4, silver is commonly used in medical
devices such as in burn wound dressings, wound care products,
catheters, orthopedic and dental implants, heart valves, and
bone cements, which are typically in direct contact with skin,
blood, and/or bones. In this subsection, we will discuss the
silver exposures originating from (i) burn wound dressing with
dermal contact, (ii) medical devices with bone contact, such as
orthopedic and dental implants, or bone ﬁlling products, and
(iii) implants with permanent blood contact such as catheters,
stents, or shunts.
5.2.1. Dermal Contact: Burn Wound Dressings. Beneﬁts
from silver therapeutics and silver-releasing dressings on wound
care and regeneration products with regard to their
antimicrobial eﬃcacy have been well studied (see also examples
given in section 4). Yet, little is published on how the released
silver ions inﬂuence the wound bed, or how they are
metabolized and deposited in the tissue. Wound dressings are
especially used on burned skin, and dermal absorption of silver
and elevated silver levels in plasma and urine were observed
after treatment with such dressings.438
Figure 21. The three main exposure sites of the human body for the
contact with silver compounds.
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Diﬀerent processes are implicated in the burn wound repair
such as inﬂammation around the site of injury, angiogenesis and
the development of granulation tissue, repair of the connective
tissue and epithelium, and remodeling. However, wound repair
is slowed due to the bacterial colonization that prolongs the
inﬂammatory response, which may also damage the surround-
ing tissue.439 To support the wound healing by maintaining a
microbe-free and a moist wound healing environment,440 silver-
based dressings are often used to prepare the wound for
healing. Over the past years, there was a rapid increase in the
number of silver dressings. Several silver products, such as silver
nitrate, silver [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)-
azanide better known as silver sulfadiazine (SSD),441 and
introduced as gold standard by Fox in 1968 (Figure 22),442
SSD/chlorhexidine, SSD with cerium nitrate, and a SSD
impregnated lipidocolloid wound dressing205,441,443 have been
used for topical burn wound therapy.
Previously reported eﬀects of silver nitrate on burn wounds
were based on clinical studies and observations showing that
concentrations exceeding 1% (1 × 107 μg L−1) of silver nitrate
were toxic to tissues. Hidalgo et al.444 showed in vitro that, at
direct exposure, AgNO3 greatly inhibits the growth of bacteria
starting at concentrations as low as a 0.0055% solution of
AgNO3 (5.5 × 10
4 μg L−1) in puriﬁed water, a level
approximately 100 times lower than those used in clinical
practice. Although ionic silver is said to have a beneﬁcial eﬀect
of decreasing wound surface inﬂammation,440,445 some studies
have recently shown a potential silver toxicity of SSD on
various host cells and a delayed wound-healing pro-
cess.446−449,449,450 Such contradictory studies reﬂect the
literature. Thus, in vitro and in vivo studies do not always
fully concur with each other,451,452 and in vitro cytotoxicity
alone cannot predict the in vivo toxicity. Indeed, there are few
in vivo studies on the eﬀect of silver in the wound healing
process. Kjolseth et al.453 used a wound healing model in adult
mice to study the eﬀect of AgNO3 and SSD on wound
epithelialization (regrowing process of skin over a wound) and
neovascularization (formation of new blood vessels). They
concluded that silver nitrate did not delay the epithelialization
and neovascularization in the treated wounds. This is in
contradiction with in vitro studies using silver salts423,454 in
which delays in wound healing, with variations in epithelializa-
tion and tissue vascularization, have been observed. It is
important to note that certain toxic eﬀects of silver (both on
ﬁbroblasts and on microorganisms) are apparently attenuated
in vivo by the presence of human serum, other biological ﬂuids
containing chloride, peptides, and proteins,455,456 or by body
ﬂuid dilution. In contrast to silver nitrate and SSD, newly
innovated silver-based dressings in which silver itself is
incorporated within the dressing rather than being applied as
a salt, compound, or solution have been introduced. The most
common form of silver found in the silver-based dressings is the
so-called nanocrystalline silver, which diﬀers from silver salts.393
Nanocrystalline silver products are said to provide small Ag(0)
clusters, which are apparently far less rapidly deactivated by
chloride or organic matter than the ionic form.457 In
comparison to ionic silver, nanocrystalline silver seems to
dissolve in water to provide both Ag(I) and Ag(0), whereas
other silver sources release only Ag(I).393 Indeed, such new
generation products available on the market have a more
controlled and prolonged release of silver to the wound area as
compared to cream formulations such as SSD. This mode of
silver delivery allows the dressings to be changed less
frequently, thereby reducing the risk of nosocomial infections,
the cost of care, as well as further tissue damages and patient
discomfort.458,459 Thus, silver compounds and nanosized silver
coatings are examples of very well established and frequently
used biomaterials with good antimicrobial and biocompatibility
properties. They are used despite increased silver levels in the
urine438,460 and some (in vitro) studies, which might indicate
the contrary.444
5.2.2. Bone Contact: Orthopedic and Dental Implants
and Bone-Filling Products. Next to our skin, silver can also
be in close contact with bone when it is used as a coating for
metallic biomaterials or when it is used as AgNPs in bone
grafts,461 in bone cements,462 and with HA on implant
surfaces.463 The main applications are here the orthopedic
and dental implants. Especially for the latter, where exposure to,
for example, bacteria-containing saliva can hardly be avoided,
strong antibacterial properties in combination with a good
biocompatibility of the implants are required to prevent
dramatic consequences such as jawbone infection464 and even
the loss of denture. Wound infection can however occur as well
for all other implants inserted into the body via operations. On
the market, metallic alloys, selected for their excellent
mechanical properties, resistance to corrosion, and biocompat-
ibility, are available with metallic silver coatings to overcome
bacterial infections. They were shown not to provoke any
histological change or functional deﬁcit of the organs and no
local and systemic side eﬀects despite elevated silver
concentrations (see section 4.1).312,313 A study465 on the
dose-dependent eﬀects of silver demonstrated that elementary
silver exhibits no cytotoxic eﬀect, at a dose below 143 μg kg−1,
on osteoblasts in vitro and even stimulates osteogenic
maturation. Bone repair itself is a highly concerted process
involving osteogenic stem cells, osteoconductive surfaces, and
osteoinductive growth factors that can be severely disrupted by
bacterial toxins and host inﬂammatory responses.466 Osteointe-
gration (or osseointegration) is thus deﬁned as direct contact
between living bone and implant, ﬁrst described by Branemark
and co-workers,467 and inﬂuenced by various factors such as the
design and size of the implant or the surface characteristics of
the medical device.468−471 Because surgeries and the occurrence
of multiresistant bacteria cause signiﬁcant medical costs, tissue-
engineered silver bone graft devices have been developed to
simultaneously prevent infection while promoting bone
regeneration. For instance, Zheng et al.466 demonstrated that
metallic AgNP-poly(lactic-co-glycolic acid) (PLGA) composite
grafts with strong antibacterial properties did not inhibit the
adherence, proliferation, or mineralization of MC3T3E1
preosteoblasts, and no negative eﬀects on the bone
morphogenetic protein 2 (BMP-2) osteoconductivity were
observed. Another group304 has investigated the biocompati-
bility of silver-coated external ﬁxation devices, speciﬁcally the
interactions of silver with tissue cells. They have shown that
silver is neither genotoxic nor cytotoxic and is comparable to
stainless steel, a material that is widely used for metal implants.
Figure 22. Structure of silver sulfadiazine.
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Moreover, silver coatings caused no cell-cycle delay and
revealed good osteoblast activity at long incubation periods.
However, the gradual loosening of implants from the bones has
been observed, particularly when the implants were ce-
mented.472 Yet, in vitro studies of bone cements made of
poly(methyl metacrylate) (PMMA) loaded with AgNPs did not
display cytotoxicity on human ﬁbroblasts and osteoblasts.352 A
new generation of PMMA/Ag2O bone cements with collagen
coating developed by Cavalu and co-workers473,474 was shown
to be capable of releasing Ag(I) during a 3-week incubation in a
simulated body ﬂuid with ion concentrations approximately
equal to those of human blood plasma. With this PMMA/Ag2O
cement, biomineralization, biocompatibility, and antibacterial
properties were improved.
Although some researchers consider that simply the
nanoscale topography of the surface of an implant is suﬃcient
for promoting osteoblast proliferation and therefore bone
remineralization,475 others have attempted to develop implants
with bioactive nanoscale surfaces to promote cell adhesion and
bone growth. For example, HA or calcium phosphate coatings
contribute to the recalciﬁcation of natural bone around the
implant thanks to their combination of nanoscale topography
and the reservoir of raw material. Such materials, like the
cosputtered Ag-containing osteoinductive HA coating on
metallic surfaces,353,476 developed to accelerate bone attach-
ment in orthopedic implants, show no in vitro cytotoxic eﬀect
and promote osteocalcin production (phenotypic marker of the
late diﬀerentiation state of osteoblast-like cells for osteoinduc-
tion and bone mineralization). Therefore, silver addition can
apparently stimulate the osteocalcin gene to promote bone
mineralization and help the rapid bone in growths in vivo.
However, further studies are required to ﬁnd out the detailed
interaction of silver ion with the osteocalcin gene.
5.2.3. Blood Contact: Implants Introduced into the
Vascular System. Almost all implants will come at some point
into contact with blood. Many polymeric materials such as
catheters, vascular grafts, stents, and prosthetic heart valves are
even directly introduced into the vascular system and
constantly in contact with blood. However, a high number of
bloodstream infections and local blood thrombosis have been
observed in relation with such implants, and researchers thus
started to focus on the development of bioinert and
biocompatible coatings for polymer surfaces to minimize
nonspeciﬁc adhesion and inﬂammatory events.477 PU-based
polymers are typical examples.397 Polyester-type waterborne
PU containing up to 3 × 104 ppb (3 × 104 μg kg−1) AgNPs478
and PU coated with polyaniline-AgNPs (0.2 wt %)
composite479 show good physiological properties in vitro (for
ﬁbroblasts, endothelial cells, platelets, and monocytes). Another
polymer, PLLA, was shown to remain biocompatible in vivo
with a coating containing up to 5 wt % AgNO3 (5 × 10
7 μg
kg−1).480 Recently, Qureshi et al.358 conﬁrmed that the AgNP-
PLLA nanocomposite ﬁlms with a AgNP concentration of
7 × 105 ppb (7 × 105 μg kg−1) had little eﬀect on the viability
of human HeLa cells (see also section 4.1.3). In addition, silver-
coated polypropylene mesh used in a rat abdominal model481
has shown in vitro and in vivo combined antibacterial eﬃcacy
with a good biocompatibility as well as tissue integration.
From all of these implants treated with silver and its
compounds discussed in this section, silver can in principle be
released and, via the bloodstream, reach all organs in the human
body, which will be discussed in the following subsection.
5.3. Eﬀects of Silver Exposure on Tissues and Organs
With the increasing use of silver, the question of its toxicity
becomes more and more an issue as so many sometimes
contradictory studies are published. Surprisingly, silver is better
tolerated by the body than most heavy metals,482 and it is
Figure 23. Absorption, distribution, metabolism, and excretion (ADME) processes of nanosilver. Adapted with permission from ref 485. Copyright
2009 Informa Healthcare.
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relatively nontoxic to mammalian cells. Most humans are
exposed every day to very low levels of silver mainly from food
and drinking water, but also to a smaller extent from air
(1 × 10−6 μg L−1).436 The average concentration of silver is
0.2−2.0 ppb (0.2−2 μg L−1) in surface water of lakes and rivers,
and 200−300 ppb (200−300 μg kg−1) in soils.483 Silver
poisoning, however, only occurs among people chronically
exposed to silver. As more and more nanomaterials are
produced, some of these materials do exhibit signiﬁcant toxicity
to mammalian cells even if they are biochemically inert and
biocompatible in bulk.484 Therefore, the exposure to nanosilver
in the body is becoming more signiﬁcant, and silver in the form
of nanoparticles has gained an increasing access to tissues, cells,
and biological molecules within the human body as shown, for
example, in sections 5.1 and 5.2. Once silver compounds are
absorbed by the body, three processes are possible, (i)
metabolism, (ii) storage, and (iii) excretion, which can result
in acute or chronic eﬀects including tissue and organ damages
as will be discussed in the following.
5.3.1. Acute and Chronic Toxicity of Silver. Toxic
substances, with regard to human health, cause short-term or/
and long-term eﬀects based on their fate in the human body as
described by the administration/distribution/metabolism/ex-
cretion process (ADME)485 depicted in Figure 23. Short-term
or acute eﬀects have a relatively quick fate (usually minutes to
days) after a brief exposure to a relatively high concentration of
toxic material (acute exposure), and they can be local or
systemic. Upon close contact with skin, eyes, lungs, or
gastrointestinal tract, local eﬀects of the toxicant can be
observed rapidly, whereas systemic eﬀects are observed later
after absorption of the toxicant into the body from its initial
contact point, after transport to other body parts, causing
possible adverse eﬀects in susceptible organs.
In the literature, only few studies486 describe in vivo results
concerning the cytotoxicity of silver. Some report a chronic
inﬂammatory reaction in patients treated with a silver-coated
heart valve even though the silver blood concentration did not
exceed 22 ppb (22 μg L−1),420 while other studies describe no
cytotoxic eﬀect of silver and a good biocompatibility.276 For
instance, for clean wounds in pigs, SSD was shown to increase
the epithelialization rate by 28%, indicating a beneﬁcial eﬀect in
wounds additional to antimicrobial activity.487 These contra-
dictory results can be explained by the variation of the silver
concentration acting on diﬀerent cell types. It is well-known
that silver toxicity is a dose-dependent process. The estimated
fatal dose of AgNO3 is 1.4 × 10
5 μg kg−1 for humans.488 Most
of the quantitative safety data on silver come, however, from a
large number of animal studies done in the past century. Thus,
the oral lethal dose, 50% (LD50), which is the amount of the
substance required, usually per body weight, to kill 50% of the
test population reported for AgNO3 is 0.5−1.29 × 105 μg kg−1
for mice, depending on the references,489and an LD50 of
2.8 × 106 μg kg−1 for rats (1.0 × 106 μg kg−1 for mice) is given
for the relatively insoluble silver oxide.490 Female SJL (H-2s)
mice (Swiss mouse inbred by James Lambert) developed serum
IgG antinucleolar antibodies after a 5−10 week treatment with
0.05% (5 × 105 μg L−1) or 0.01% (1 × 105 μg L−1) AgNO3,
administered orally in drinking water.491 Controls receiving
ordinary tap water and mice treated with 0.002%
(2 × 104 μg L−1) AgNO3 showed no antinucleolar antibodies.
Serum autoantibodies to chromatin or histones, kidney, spleen,
stomach, thyroid, or skin antigens (except the nucleolus) were
not found in any of the mice. In mice given 0.05%
(5 × 105 μg L−1) AgNO3, the kidney showed the highest
silver concentration ((1.22 ± 0.9) × 104 μg kg−1 wet wt),
followed by the spleen ((8.7 ± 1.3) × 103 μg kg−1 wet wt), and
the liver ((3.9 ± 0.4) × 103 μg kg−1 wet wt). Lower
concentrations of 0.01% (1 × 105 μg L−1) AgNO3 caused a
diﬀerent distribution of silver, with the highest concentration
now in the spleen ((2.1 ± 0.16) × 103 μg kg−1 wet wt),
followed by the kidney ((6.3 ± 0.37) × 102 μg kg−1 wet wt)
and the liver (<(0−29) × 103 μg kg−1 wet wt). Silver seems
thus to be a more speciﬁc inducer of antinucleolar/
antiﬁbrillarin autoantibodies than mercury and gold, lacks the
general immune stimulating potential of mercury, and has only
a weak tendency to induce renal immune deposits.491
Chronic toxicity of silver is observed with argyria, which was
observed in individuals that have ingested both metallic silver
and silver compounds in small doses over months. To induce
argyria by ingestion, the estimated required amount lies within
the range of (1.4−40) × 104 μg kg−1 for soluble silver
salts.488,492 Argyria is permanent, and most medical doctors and
scientists believe that the discoloration of the skin seen in
argyria is the most serious health eﬀect that silver may
provoke.483 While the silver level in the blood in argyremic
patients is reported to vary from nondetectable to 5 μg L−1,493
levels below 2 μg L−1 in the blood are considered as normal460
based on daily incorporation of small amounts of silver. Indeed,
only a fraction of it (almost 10 wt %) is absorbed,494 the rest
being excreted in feces.438,494 The absorbed fraction is carried
by the bloodstream and deposited in various tissues throughout
the body in which silver is stored and accumulated intra-
cellularly apparently without any eﬀect.494 Most of the ingested
silver is then excreted via the urine.438,494
However, therapeutic and toxic eﬀects can be only exhibited
by free Ag(I) (see section 4). Therefore, the reported threshold
values have to be interpreted with caution, because the
measured silver ion concentration may include both bound
and free silver. In the literature, the cytotoxicity of silver nitrate
on mammalian cells has been reported: the half maximal
inhibitory concentration (IC50), which described the eﬀective-
ness of a compound in inhibiting biological or biochemical
function, is 721 ppb (721 μg L−1) for L929 mouse ﬁbroblasts
and 470 ppb (470 μg L−1) for MC3T3-E1 mouse osteoblasts
after 8 days of incubation in Eagle’s minimal essential medium
(MEM).495
Apart from these more general toxicity aspects, the eﬀects of
silver on individual organs have been studied, which will be
discussed in more detail in the next subsection.
5.3.2. Tissue and Organ Damages. After an overexposure
followed by absorption, silver is transported by the bloodstream
and can accumulate in organs and tissues such as liver, skin,
kidney, spleen, heart, lung, olfactory bulb, corneas, gingival
mucous membranes, brain, and testes.438,496−502,502,503 Several
systemic clinical side eﬀects of silver may occur, such as
argyrosis (eye), leucopenia, or liver and kidney dam-
age.420,430,496,504 For instance, histopathological analysis of
liver tissue showed a dose-dependent toxicity of silver494,505 and
an inﬂammation with an inﬂux of lymphocytes, but values can
recover after aborting silver uptake.438
Reports concerning the toxic eﬀects of silver related to nerve
tissue, centrally and in the periphery, are rather rare. However,
silver has been claimed to cause brain damage,506 seizure,507 a
persistent vegetative state,508 or in early studies even the death
of the animal.509,510 Moreover, Horner et al.511 intoxicated mice
with an intraperitoneal injection of LD50 amounts of diﬀerent
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silver compounds and observed toxic syndromes including
hyperexcitability, ataxia, central nervous system depression, loss
of righting reﬂex, and death of mice. At lower doses, diﬀerent
toxic eﬀects have been reported. For example, local neuro-
toxicity was reported in a patient 5 years after the use of silver-
impregnated bone cement512,513 in a revisional Christiansen
total hip arthroplasty. After serum analysis, silver-impregnated
bone cement was shown to release a high silver concentration
in the hip joint cavity leading to the peripheral nerve lesion. If a
large amount of silver is released from the implanted bead (only
10% of the loaded silver remained on the bead surface) into
connective tissue, severe local tissue disruption and even
necrosis can be induced.514 For silver-coated heart valves,
hypersensitivity or allergic reactions were described.515,516
The severness of tissue damage seems thus to be dose
dependent, and low concentration of silver compounds appears
to be administrable without lethal side eﬀects.
5.3.3. Cellular Uptake of Silver. As mentioned before, the
nanoparticles in general can get into the body through
semiopen interfaces (Figure 23). On the cellular level, modes
of the internalization include either passive diﬀusion192,517,518
or active endocytic pathways, such as (i) macropinocytosis, (ii)
phagocytosis, (iii) clathirin-mediated endocytosis, (iv) caveolar-
mediated endocytosis, and (v) clathirin-independent and
caveolin-independent endocytosis (Figure 24).192,519,520 These
processes seem to depend on the size and the shape of the
nanoparticles.517,519 In a study by AshaRani et al.,192 the
presence of endosomes ﬁlled with AgNPs, as seen on TEM and
scanning TEM images, suggests a receptor-mediated endocytic
pathway rather than a diﬀusion process. One way to elucidate
how particles enter the cell is the selective inhibition of the
diﬀerent pathways. For example, treating human macrophage
cell line U937 with diﬀerent inhibitors, such as chlorpromazine,
nystatin, and cytochalasin D, and measuring subsequent
production of Interleukin-8, Kim and Choi517 proposed a
complex mechanism, including endocytosis and phagocytosis,
for the uptake of AgNPs. The same authors proposed, in
addition, direct penetration, because of the observed cell
death.517 On the other hand, Greulich et al.521 investigated
uptake of PVP-coated AgNPs by human mesenchymal stem
cells. Using inhibitors, such as chlorpromazine and wortman-
nin, the main uptake through clathirin-mediated endocytosis
and macropinocytosis was indicated, respectively.521 For more
detailed information about the general mechanism of cellular
uptake of NPs, the reader is directed to recently published
reviews in this ﬁeld.519,520,522
5.4. Toxic Eﬀects of Silver Nanoparticles
Since the recent developments of AgNPs in medical
applications (see section 4), their toxic eﬀects have also to be
studied. Indeed, AgNPs interact with bacteria and viruses (see
section 3) and with the eukaryotic immune system, as will be
shown in the following.
Toxic eﬀects of AgNPs have been reported for diﬀerent in
vitro and in vivo mammalian systems.523−528 Indeed, AgNPs
can potentially cause toxic eﬀects, such as inﬂammation, cell
activation, depletion of GSH level in association with
mitochondrial dysfunction, and ROS production.529 Indeed,
AgNPs interact with thiol-containing proteins and enzymes,
such as thioredoxin peroxidase, thioredoxin, superoxide
dismutase protein, and GSH (the most sensitive indicator of
the cell to silver toxicity). The so-induced ROS accumulation
can initiate an inﬂammatory response, a perturbation, and a
destruction of the mitochondria.530 Arora et al.531 conﬁrmed in
vitro an induction of oxidative stress with a depletion of GSH
and an increased lipid peroxidation when human cell lines were
exposed to AgNPs. Finally, all of these processes gradually lead
to necrosis and/or programmed cell death (apoptosis).532,533 It
has been found that apoptosis was induced by a lower silver
concentration than the one required for necrosis.531 However,
how exactly AgNPs do induce cytotoxicity is still not well
understood. Lubick et al.534 suggested that AgNPs can be taken
up by organisms, thereby introducing a continuous release of
Figure 24. Possible modes of AgNPs internalization. Adapted with permission from ref 519. Copyright 2010 Macmillen Publishers Ltd. Adapted
with permission from ref 520. Copyright 2011 Springer Science and Business Media.
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silver ions into the tissues by bypassing the mechanism of silver
ion detoxiﬁcation, discussed in section 5.4. As was already
mentioned in the context of bacteria (see section 3.1), it has
recently been suggested that AgNPs may act as Trojan horses
by entering the cells and then releasing silver ions that damage
intracellular functions.527 Recent publications reviewed the
human risk assessment for nanoforms of silver (e.g., AgNPs)498
and the toxicology and toxicokinetics of nanosilver.535 One
should keep in mind that the main in vitro mechanism seems to
be mediated by an increase in ROS production. This stimulates
oxidant-sensitive signaling pathways, which at high doses
stimulate inﬂammation, leading to a secondary genotoxicity
and cell death (apoptosis or necrosis).
Smaller particles exhibit not only a higher toxicity as
compared to larger particles due to their larger surface area
availability and thus a stronger ion release (as explained in
section 3.1), they can in addition cross more easily the
biological barriers, such as the blood−brain536,537 or the
blood−testes barrier.537,538
5.5. Silver Detoxiﬁcation
Although the antimicrobial activity of silver is well-known, little
is known about the eukaryotes’ detoxiﬁcation mechanisms. The
question is often raised why silver does not have similar
cytotoxic eﬀects toward eukaryotic cells compared to bacterial
cells. Eukaryotic cells are usually larger with a higher structural
and functional redundancy as compared to prokaryotic cells,
and therefore higher silver ion concentrations are required to
achieve comparable toxic eﬀects as for bacterial cells.27 This
diﬀerence provides a “therapeutic window” (see section 4) in
which bacterial cells are successfully attacked, whereas harmful
eﬀects on eukaryotic cells are not yet observed. From the
literature, several modes of silver detoxiﬁcation exist in
eukaryotic cells: (i) the sequestration of silver ions and (ii)
the ATPase eﬄux pump.
5.5.1. Sequestration of Silver Ions. The principal
sequestration agents for transition metal ions in groups 11
and 12, including Cu(I) and Ag(I), are sulfur-containing
molecules such as sulﬁdes494 or the cysteine-rich metal-
lothioneins (see also section 2.2).539 One of the ﬁrst observable
interactions of silver salts in contact with the skin are black,
insoluble precipitates discussed as sulﬁdic compounds.540
Surprisingly, their exact composition is still not known.
However, many organisms use sulﬁdes to precipitate the excess
of metals. The precipitation of silver ions (Figure 25) in the
form of silver sulﬁde, but also as silver phosphate or silver
chloride, renders Ag(I) less bioavailable due to the low
so l ub i l i t y o f t h e s e compound s (K S P ( 25 °C) :
Ag2S = 6 × 10
−51 mol3 L−3, AgCl = 1.8 × 10−10 mol2 L−2,
Ag3PO4 = 8.89 × 10
−17 mol4 L−4).194 However, the nature of
the solutes can aﬀect the biological activity of silver, for
example, by complex formation, thus inﬂuencing the amount of
silver in solution. In, for example, phosphate-buﬀered saline
(PBS), silver can be active in concentrations as low as 50 ppb
(50 μg L−1), but the presence of organic matter signiﬁcantly
diminishes the eﬃciency of silver. Nutrient broths decrease the
eﬃciency of silver by a factor of at least 80 as compared to pure
water,541 and serum decreases the activity by a factor of more
than 250.542 Serums are an extremely complex mixture of
plasma proteins, growth factors, hormones, etc. The exact
mechanism involved in serum-promoted silver release is still
Figure 25. Overview on currently discussed species of Ag(I) and Ag(0) and their interactions with biomolecules starting with their release from
surfaces such as catheters or implants (KSP(25 °C): Ag2S = 6 × 10
−51 mol3 L−3, AgCl = 1.8 × 10−10 mol2 L−2, Ag3PO4 = 8.89 × 10
−17 mol4 L−4).194
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unknown, but the presence of sodium and chloride ions has an
eﬀect on silver dissolution. Thus, Burd et al.543 showed that
when the dressing was presoaked in PBS, the release of silver
was increased, leading to a decrease of the silver concentrations
remaining on the dressing, and the in vitro toxicity of silver in
both keratinocyte or ﬁbroblast culture media was lowered.
Indeed, Hidalgo and co-workers444 also demonstrated that
viability inhibition of ﬁbroblasts varies according to the
concentrations of fetal calf serum (FCS) present in the
medium. AgNO3 was 10 times less toxic in a medium
supplemented with 10 wt % FCS than with 2−5% FCS.
These results suggested that FCS in the culture media
inactivates AgNO3 or protects the ﬁbroblasts against the toxic
eﬀects of this compound. Such cytoprotective eﬀects of serums
have also been described and conﬁrmed by other research-
ers,544,545 however, without a full description of a molecular
mechanism.
The previously mentioned argyria (see section 5.3.1) is an
eﬀect resulting from Ag-sequestration in the body. Such
pigmentation caused by silver ingestion, as well as tattoos
(pigmented lesions caused by amalgam), are examples of silver
remaining in the body for an extended period without causing
other harm.546 In the case of argyria, White et al.547
demonstrated the presence of silver, sulfur, and selenium in
the basement membrane and elastic ﬁbers. Aoyagi and
Katagiri546 also reported the presence of silver and sulfur in
connective tissues without host reaction. Using an original
subcutaneous injection method, Aoyagi and Iwasaki548 have
implanted silver particles of two diﬀerent sizes (100 nm and
45 μm) and have observed the sulfuration of silver and
histopathologic changes during a year. From the obtained
results, they concluded that the decline of silver eﬀect on the
host was correlated with an increase in the sulfuration of silver.
The storage of silver in form of Ag2S or S-bound species in
general seems thus apparently an eﬃcient way of detoxiﬁcation.
Another prominent example for the importance of sulfur-
containing compounds are the metallothioneins already
mentioned in section 2.2. Metalloproteins in general protect
the human body against oxidative stress induced by excess free
radicals. The synthesis of MT is transcriptionally regulated by
metals in all higher eukaryotes,539 and its production promotes
RNA and DNA synthesis, cell proliferation, and tissue repair.
Thus, MTs found in animals, higher plants, eukaryotic
microorganisms, and some prokaryotes539 have the dual eﬀect
of protecting the tissues against the potential toxic eﬀects of
silver and of improving natural healing. Indeed, the uptake of
silver ions by the cells stimulates MT synthesis and leads to the
formation of stable complexes, such as Ag-MT with
luminescent properties.549 The metallothioneins are still
subjects of scientiﬁc investigations due to their vital roles in
mineral transport, enzyme production, signal transduction,
redox reactions, and many other crucial biological functions.
In summary, silver is thought to be bonded to the host
substances mainly through the coordination by sulfur, thus
leading to a reduced toxicity of the metal ion.
5.5.2. Silver Ion Transport by ATPase P-type Eﬄux
Pumps. We have discussed in section 3.2 that the bacterial
resistance of silver consists of two mechanisms: (i) the
accumulation and storage of silver (generally redox chemistry)
and (ii) the active eﬄux pump, in which conserved regions of
P-type ATPase associated with the transport of copper pump
the silver ions out of the cell. ATPase pumps are ubiquitous and
highly conserved from bacteria to humans.550−552 In mamma-
lian cells, they are present in the plasma membranes or
endoplasmic reticular membranes, whereas in prokaryotes they
are located in the cytoplasmic membranes. ATPases, which
translocate ions such as protons, Na(I), K(I), Ca(II), and a
variety of metal ions, are categorized into the P-type family of
ATPases553 that use the energy provided by the ATP hydrolysis
to transport ions across cell membranes. In eukaryotes, P-type
ATPases play essential roles in numerous processes, which in
humans include nerve impulse propagation, relaxation of
muscle ﬁbers, secretion and absorption in the kidney,
acidiﬁcation of the stomach, and nutrient absorption in the
intestine.554
Similar to bacterial cells, silver has been shown to use the
copper transporter in eukaryotic systems, such as ATP7A that
transports the intracellular silver in copper-resistant Chinese
hamster ovary cells (CHO-CUR3) and in human ﬁbroblasts to
the plasma membrane for excretion.555,556 ATP7A and the
related ATP7B are well characterized as copper transporters
with distinct distribution in tissues. Both play an equally
important role in regulating copper levels in the body and in
maintaining intracellular copper concentration.557 These two
transporters utilize the same general mechanism for their
function, and are coexpressed in some cells, but they have
diﬀerent traﬃcking properties. While ATP7B is more
specialized, ATP7A has been found to be a “house-keeping”
enzyme due to its higher turnover rate for the formation of
phosphorylated intermediates558 as compared to ATP7B.
ATP7A exports copper from the enterocytes (or intestinal
absorptive cells) into the blood circulation for further
distribution throughout the body.559 Inactivation of ATP7A
in Menkes Disease results in increased copper concentration in
the intestine.560 Removal of excess copper from the body
requires the presence of ATP7B in the liver.561 ATP7B
facilitates transport of copper from hepatocytes into the bile.562
Thus, the inactivation of ATP7B in Wilson’s disease is
associated with a massive copper overload in the liver and
some other tissues.560 Silver transport by these transporters is
expected to take place in an analogous fashion.
Another monitored protein, CTR1, has an important role in
regulating the Cu(I) uptake at the cell membrane in
mammalian cells by transporting copper with high aﬃnity in
a time-dependent and saturable manner.563 This protein can
similarly handle silver and other metals.563−565 However, little
is known about the expression and function of CTR1 for either
silver or copper transport.566 Because of the aforementioned
close similarity between Cu(I) and Ag(I) (see, for example,
sections 2.1 and 2.2), it is not surprising that silver ions were
found to interact with important copper transport proteins such
as ATP7 and CTR1.
To conclude, AgNPs and all implants treated with silver and
its compounds release Ag(I), which are ﬁrst absorbed by the
body and then transported via the bloodstream to be
accumulated mainly in the liver and spleen, causing some
side eﬀects in a dose-dependent manner. For the time being,
little is known about the mechanisms involved in the silver
transport and detoxiﬁcation in the human body. Because silver
is a nonessential element for our human body, Ag(I) has to use
already existing transport ways for other, essential elements.
Analogies can be made (i) on the basis of the similarity of ATP
pumps ranging from bacteria to humans, and (ii) by direct
comparison with Cu(I) transport due to the comparable
properties of Cu(I) and Ag(I) (see, for example, sections 2.1
and 2.2). Thus, according to numerous predictions, silver may
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use the already existing Cu-transport systems. Nevertheless, the
real pathway still remains to be elucidated.
The determination of a “therapeutic window” and the
toxicity or the biocompatibility of silver nanomaterials and
silver-coated implants is crucial for their successful application.
Nonetheless, this is also one of the main diﬃculties because
some in vivo and in vitro studies give contradictory results
depending on the used models and conditions.
6. CONFLICTING EVIDENCE
This Review on the current state of the art of research on silver
and its compounds in the medical context shows that most
results need to be interpreted with care and that further
investigations are needed. For instance, wound care studies,
trying to compare diﬀerent products, have been carried out by
several research groups, but varying silver concentrations and
diﬀering modes of delivery of silver ions (test setup) make a
direct comparison inappropriate.439,567−570 Another example
showing the diﬃculties in the interpretation of the obtained
results lies in the in vitro antimicrobial tests. For instance,
laboratory studies usually begin with the evaluation of the
determination of the MIC of an antimicrobial agent to
determine its potency. Numerous factors, however, inﬂuence
the activity, such as the concentration, the temperature, the
contact time, the type of tested species, the number of
organisms present, and the presence of organic matter.221,571
This is why such MIC-values may vary from one literature to
another. Furthermore, recent studies of 3D cell cultures show
that, for example, skin cells are better able to survive exposure
to cytotoxic agents such as silver nitrate than in 2D cultures.572
Because 3D cell cultures have only recently become more
standardized for investigations, the literature currently lacks
more abundant results. Along the same lines, we have also
pointed out the often contradictory results obtained for in vivo
as compared to in vitro studies (see sections 3 and 5). In this
context, equilibria of insoluble silver compounds with soluble
biomolecule complexes are often cited, but the nature of the
latter remains largely unknown, and as insoluble silver
compounds, AgCl is as often mentioned as Ag3PO4 or Ag2S,
although the solubility products of these are very diﬀerent.
Another ongoing discussion is the question whether bacteria
can become resistant to silver. We have described indeed
several defense mechanisms of bacteria against silver: the eﬄux
pumps and silver reducing mechanisms. A recent review573
describes thus that bacteria and fungi are able to biosynthesize
AgNPs of 5−40 nm from relatively high concentrated AgNO3
solutions (1 × 103 μM, 1.08 × 105 μg L−1).183 If such properties
are encoded in genes, they are very likely to be transmissible,
either by heritage or by horizontal transfer. However, given the
wide range of possible interactions of silver ions with
biomolecules, chances of absolute resistance against silver as
for antibiotics are probably very much smaller. The main
concern for applicability will thus be to remain in the
“therapeutic window”.
Studying the literature along this Review, we also discovered
discrepancies in the description of AgNPs, “nano-silver”, and
silver clusters in diﬀerent papers mentioned in this Review. It is
not clear if the same or diﬀerent species are described, for
example, for clusters formulated as “Ag4” and “Ag4
2+”, as the
analytical methods to analyze these clusters were diﬀerent.
Mass spectrometry certainly would reveal rather the charged
species, and at the same time may lead to fractionation of
clusters, thus falsifying the results. XPS studies, on the other
hand, may give better insights into the oxidation state of the
metal directly in the tissues. This method is however less used
by biochemists and microbiologists. The term “silver nano-
particles”, AgNPs, is also widely used and may describe very
diﬀerent sizes of NPs, on one hand, as well as very diﬀerent
surface chemistry of the latter. Thus, some studies come to the
conclusions that AgNPs are rather toxic, while others describe
them as well tolerable by the mammalian organism. Certainly,
the size of the AgNPs plays just as important of a role as its
surface functionalization. Their surface charge is important if
these particles should be taken up easily or not, if they are
hydrophobic or hydrophilic, and thus soluble rather in apolar,
respectively polar, environments.
7. CONCLUSIONS
We have brought together in the previous sections the results
related to the interaction of silver and its compounds with
living cells, giving an integrating view from the materials via the
microscopic to the molecular scale. While on the materials side,
a lot of facts are conﬁrmed, the antimicrobial properties
observed at the nano- and microscale are more diﬃcult to ﬁt to
the molecular observations. The way from hypotheses to a full
molecular mechanism of action of the silver ions in biological
media is still long, and a lot of bridges need to be built between
the research areas. While some results and opinions seem to be
diametrically opposite, they often are based on experiments,
which cannot be compared directly with each other. It is
established by now that the interactions of silver and its ions
with human and bacterial cells take place on many molecular
levels. Thus, the current state of research on silver and its
compounds in medicine resembles a very large puzzle of which
partial areas give a local picture on the mechanism, while other
areas are still mainly incomplete. A number of diﬀerent
hypotheses, sometimes of opposite conclusions, are derived
from individual results to propose the missing links. However,
these have to be conﬁrmed yet to complete the “silver puzzle”
and to understand the overall reactions and underlying
mechanisms of its action.
We have seen in these past sections that, although many
results on silver and its interactions with biological media such
as body tissues and ﬂuids as well as individual biomolecules can
be found in the literature, a global picture on the functioning is
still missing. Many contradictory studies conﬁrm that the story
about silver and its good antimicrobial properties and good
biocompatibility is by far not ﬁnished. Silver deﬁnitely has a
great potential in the medical context as long as its
concentration can be well controlled. With further studies,
the potential for applications in other ﬁelds such as nanoma-
terials is extremely high and promising.
It is thus important to foster interdisciplinary research,
regrouping scientists from all domains of natural sciences to
solve a mature problem: we have to combat bacteria, which
become more and more resistant against antibiotics. Silver and
its compounds may well be a possible solution.
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(335) Damm, C.; Münstedt, H.; Rösch, A. J. Mater. Sci.: Mater. Med.
2007, 42, 6067.
(336) Stobie, N.; Duffy, B.; Hinder, S. J.; McHale, P.; McCormack,
D. E. Colloids Surf., B 2009, 72, 62.
(337) Stobie, N.; Duffy, B.; Colreavy, J.; McHale, P.; Hinder, S. J.;
McCormack, D. E. J. Colloid Interface Sci. 2010, 345, 286.
(338) Zampino, D.; Ferreri, T.; Puglisi, C.; Mancuso, M.; Zaccone,
R.; Scaffaro, R.; Bennardo, D. J. Mater. Sci.: Mater. Med. 2011, 46,
6734.
(339) Kassaee, M. Z.; Akhavan, A.; Sheikh, N.; Sodagar, A. J. Appl.
Polym. Sci. 2008, 110, 1699.
(340) Santa Maria, L. C. de; Souza, J. D. C.; Aguiar, M. R. M. P.;
Wang, S. H.; Mazzei, J. L.; Felzenszwalb, I.; Amico, S. C. J. Appl. Polym.
Sci. 2008, 107, 1879.

ht
tp
://
do
c.
re
ro
.c
h
(341) Travan, A.; Pelillo, C.; Donati, I.; Marsich, E.; Benincasa, M.;
Scarpa, T.; Semeraro, S.; Turco, G.; Gennaro, R.; Paoletti, S.
Biomacromolecules 2009, 10, 1429.
(342) Travan, A.; Marsich, E.; Donati, I.; Benincasa, M.; Giazzon, M.;
Felisari, L.; Paoletti, S. Acta Biomater. 2011, 7, 337.
(343) Kumar, R.; Münstedt, H. Polym. Int. 2005, 54, 1180.
(344) Kumar, R.; Howdle, S.; Munstedt, H. J. Biomed. Mater. Res.,
Part B 2005, 75, 311.
(345) Damm, C.; Münstedt, H.; Rösch, A. Mater. Chem. Phys. 2008,
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